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ABSTRACT 
Traumatic brain injury (TBI) is an important clinical problem affecting 1. 7 million 
Americans annually. TBI affects peripheral organs beyond the nervous system with 
particularly profound effects on the lung, predisposing TBI patients to develop respiratory 
dysfunction due to bacterial pneumonia. Previous clinical and basic science studies have 
suggested TBI induces an immune depressed state rendering TBI patients more 
susceptible to pneumonia. As no mechanism has been proven as a cause for TBI-
induced immune modulation we created an animal model of TBI and bacterial 
pneumonia to investigate the effects of TBI on pulmonary immune function. Our model 
revealed that instead of increasing susceptibility to bacterial pneumonia, TBI results in a 
more robust neutrophil recruitment in the lung that allows for faster bacterial clearance 
and increased survival after bacterial challenge. This response is paradoxically 
accomplished with significant decreases in pro-inflammatory cytokine production. An 
important neural mediator of pulmonary inflammation is substance P which acts through 
the neurokinin-1 receptor (NK-1 R) to recruit neutrophils to the lung and increase 
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pulmonary vascular permeability. Treatment with an NK-1 R antagonist abolished the 
increased bacterial killing and recruitment in TBI mice but treatment of sham injury 
animals with an NK-1 R agonist increased their lung neutrophil recruitment and bacterial 
killing. These findings point to an important role of substance P after TBI and in the 
immune response to pneumonia. We complemented the findings in our animal model 
with patient data from the National Trauma Database comparing the incidence of 
pneumonia among TBI and non-neurotrauma patients. After matching patients by 
demographics, vital signs, hospital, and importantly injury severity score, we found TBI 
patients had a decreased incidence of pneumonia. This finding is contrary to the findings 
of previously published studies that did not account for the confounding factor of injury 
severity. Our studies offer a new perspective on immune function after TBI and possibly 
a new therapeutic approach to pneumonia in TBI and non-TBI patients alike. 
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Chapter 1 : Introduction 
Traumatic Brain Injury 
Traumatic brain injury (TBI) affects 1. 7 million people every year resulting in 
275,000 hospitalizations and 53,000 deaths making TBI the leading cause of 
injury death in the United States (25). The wars in Iraq and Afghanistan have 
resulted in another 320,000 TBI patients suffering TBI (51). Acute care for these 
injuries has cost an estimated $60 billion each year and chronic care of TBI 
patients carrying $9.2 billion in lifetime medical costs and $51.2 billion in lost 
productivity (25). 
TBI is defined as a bump, blow, jolt, or penetrating injury to the head that disrupts 
normal brain function (25). This can vary from a mild concussion with brief 
change in consciousness to severe injury with coma and permanent neurological 
deficits (45). TBI severity is assessed using the Glasgow Coma Scale (GCS) that 
scores the neurological function of a patient in 3 categories: eye opening, verbal 
response , and motor response (63). The sum of these scores reflects the 
cognitive function of TBI patient and the severity of their injury. A score of 15-13 
represents a mild TBI , 12-9 moderate TBI, 8-3 severe TBI (45). Coupled with 
imaging studies, GCS scoring is an important tool for predicting patient prognosis 
and has been shown to correlate with patient outcome (63, 132, 148). 
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Pathophysiology of TBI 
TBI involves two distinct components: primary and secondary injury. Primary 
injury is the direct result of the mechanism of trauma to the brain (57, 137). 
Secondary injury encompasses the cellular response to trauma that is initiated by 
the primary injury but may continue for days (137). Consideration of both arms of 
TBI is crucial to understanding the pathology of brain injury. 
Primary Injury 
Falls, motor vehicle accidents, and objects striking the head comprise the leading 
causes of TBI in the US (25). Each of these can result in multiple different injuries 
to the brain parenchyma. The patterns of primary injury can determine the course 
and outcome of traumatic brain injury patients (57). 
Hematomas 
Hematomas are collections of blood in the cranium that are restricted in their 
expansion by the bony confines of the skull. These are the result of disrupted 
blood vessels that, depending on their location, can have different effects on the 
brain parenchyma. Epidural hematomas involve rupture of the middle meningeal 
artery as it courses between the skull and the outer covering of the brain, the 
dura mater. Subdural hematomas are more common and stem from disrupted 
veins between the dura and arachnoid layers surrounding the brain (57). In both 
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types of hematoma, the build-up of blood in the skull cannot expand without 
compressing the surrounding structures. This increases intracranial pressure 
(ICP) that, if it exceeds the pressure of blood entering the brain, can close off 
blood vessels and cause global brain ischemia. Expanding hematomas can also 
directly disrupt and damage brain tissue and herniate brain structures through 
the structures within the skull corresponding to a very poor outcome (137). 
Contusions 
Cerebral contusions are bruises of the brain tissue with disruption of small 
vessels and local extravasation of blood in the brain parenchyma (57). These are 
usually the result of impact forces and collisions of the brain with the skull. In 
impact injuries to the skull, typically there will be a contusion to the brain 
underlying the area of impact and a contusion on the direct opposite side of the 
brain where the brain bounced off the contralateral skull surface as it accelerated 
away from the point of impact. These are known as the coup and contracoup 
injuries respectively. If the brain is accelerated in a side-to-side or front-to-back 
direction, the undersurface of the brain moves over the sharp irregular surface of 
the skull floor. This pattern of contusion is known as a gliding contusion or 
"washerboard" injury. Contusions most commonly occur in the protuberances 
and undersurfaces of the frontal and temporal lobes. These lesions vary in 
severity but can result in significant brain swelling that, like expanding 
3 
hematomas, can increase ICP and initiate progression into catastrophic brain 
damage. 
Diffuse Axonal injury 
Acceleration/deceleration injuries can also cause diffuse axonal injury (DAI), a 
widespread disruption of the white matter tracts of the brain containing axonal 
projections from the grey matter. DAI is the result of shearing force where one 
plane of neuronal tissue slides over the other severing or stretching the axons 
that traverse them . This injury can be mild like a concussion or severe with 
patients entering a persistent vegetative state and over 90% mortality (57). 
TBI and the Immune System 
Central nervous system injury has deleterious effects on immune function that 
may last months to years after recovery from the primary insult (21, 30, 78, 140). 
Initially, TBI causes a release of acute phase proteins from the liver including 
pro-inflammatory cytokines and chemokines (21, 30). As the acute phase wanes, 
TBI patients develop widespread apoptosis of lymphocytes and profound 
decreases in plasma levels of IL-2, IFN-y, and TNF-a, cytokines crucial to 
lymphocyte activation and proliferation (21, 51, 89). Monocytes from TBI patients 
produce significantly lower amounts of the pro-inflammatory cytokines IL-6, IL-
1 B, and TN F-a in response to LPS stimulation and express less major 
histocompatibility complex II (MHCII) on their surfaces resulting in impaired 
antigen presentation (51, 139). Circulating neutrophils exhibit decreased reactive 
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oxygen species formation and phagocytic function (40). Several mechanisms 
have been proposed to explain these changes that implicate different nervous 
inputs and their interactions with the cells of the immune system. 
The current hypothesis of TBI-induced immunomodulation stems from the brain 's 
ability to detect and respond to inflammation in the periphery. During the normal 
immune response to infection in the periphery, a small portion of the 
inflammatory cytokines in the circulation cross the blood-brain-barrier and 
stimulate several immunomodulatory centers in the brain, namely the 
hypothalamus and solitary nucleus (21, 72, 140). These centers then signal 
through their respective efferent pathways to peripheral immune cells to limit the 
inflammatory response to protect the body from damage caused by an 
unchecked immune response. When the brain itself is injured, the inflammatory 
cytokines released from injured brain tissue are also detected by these centers. 
The abnormally high levels of cytokines within the central nervous system are 
interpreted as reflecting high concentrations in the peripheral circulation, 
indicating an over-active peripheral inflammatory response (86, 140). These 
neural immunomodulatory pathways then go into overdrive with high levels of 
efferent signaling to quell this perceived excessive peripheral inflammation. While 
no single pathway has been shown to account for all of the observed immune 
alterations following TBI, each may play an important role in this multi-faceted 
response. 
5 
The Hypothalamic-Pituitary-Adrenal (HPA) Axis 
The hypothalamus is an important sensor and modulator of inflammation. Initial 
investigations into immune alterations after TBI suggested the stimulated release 
of the glucocorticoid cortisol from the adrenal cortex was responsible for 
depressing immune cell function (140). Cortisol has potent anti-inflammatory 
effects and induces lymphocyte apoptosis and decreased pro-inflammatory 
cytokine production. Intracerebral injections of the inflammatory cytokine IL-1 B to 
simulate tissue injury within the brain stimulate significant cortisol release (140). 
While this decreased pro-inflammatory cytokine production in the peripheral 
blood, blocking cortisol action in this model only mildly decreased the anti-
inflammatory response. Thus the HPA axis contributes to, but is not the only 
mechanism of TBI immunomodulation. 
The Sympathetic Nervous System 
The sympathetic nervous system (SNS) is termed the "fight or flight" system. It 
mediates increases in heart rate, blood pressure, and respiration through 
catecholamine release. The "catecholamine storm" in patients recovering from 
TBI is a well-documented phenomenon characterized by an abnormally elevated 
release of catecholamines from both the adrenal medulla and neuron terminals of 
the SNS (1 0). With rich innervation of lymph nodes, the spleen, and liver, these 
catecholamines interact directly with cells of the immune system through 13-
adrenergic receptors expressed on their surfaces (21, 116, 122). 
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Christian Woiciechowsky, a neurosurgeon and early pioneer in TBI 
neuroimmunology investigated the role of catecholamines and the SNS following 
TBI and their effect on immune cell function. His group found that peripheral 
blood monocytes from rats that underwent a sustained increase in ICP produced 
high levels of the anti-inflammatory cytokine IL-10 (138). IL-10 is a potent 
suppressor of the inflammatory response blocking NF-KB activation , JAK-Stat 
signaling, and TH1 lymphocyte proliferation. They also demonstrated this effect 
in patients that had suffered brainstem compression during neurosurgical 
procedures. Treatment with beta-adrenergic receptor blockers reduced the IL-10 
production and increased monocyte production of pro-inflammatory cytokines 
(39, 138). 
While these findings suggested a catecholamine-mediated mechanism for the 
immune paralysis following TBI, the studies were not conducted specifically in 
brain injury but only increased ICP and brain stem compression. The 
pathophysiology of TBI does include changes in ICP but also traumatic tissue 
injury and intracranial cytokine elaboration that make the neuroimmune response 
different from isolated rises in ICP (137, 145). Clinical studies have found that, 
while briefly elevated immediately after injury, SNS signaling and catecholamine 
surges predominate in the later phases of TBI (>14 days) making it a less likely 
mechanism for the acute changes in immune function but it may explain the 
persistence of immune dysfunction long after recovery (13, 73). 
7 
Parasympathetic Nervous System and the Vagus Nerve 
The parasympathetic nervous system (PNS) is responsible for a "rest and digest" 
response in contrast to that of the SNS. Increased PNS signaling results in a 
general slowing of the heart rate in a characteristic pattern detectable on EKG 
termed high-frequency heart rate variability (HF HRV) (13, 62). In the acute 
phase after injury, EKG studies of TBI patients demonstrate sustained high levels 
of HF HRV indicating continuous predominant parasympathetic signaling to the 
periphery (73). The majority of the PNS signaling to the periphery is mediated by 
the vagus nerve. Branches of the vagus supply the parasympathetic innervation 
of the thoracic and the abdominal viscera. Each branch carries both efferent 
motor fibers and afferent visceral sensory fibers. The efferent and afferent limbs 
both have distinct immunomodulatory functions that regulate the immune 
response in target organs (1 01 ). 
Afferent Sensory Signaling 
Vagal sensory neurons project from the viscera to the solitary nucleus in the 
medulla oblongata. These neurons detect mechanical, chemical, and 
inflammatory stimuli in the viscera and relay back to the solitary nucleus that, in 
turn, activates the dorsal nucleus of the vagus to increase efferent signaling out 
to the viscera. Sensory neurons are also capable of efferent signaling through 
the release of the neuropeptide substance P (SP) (54). 
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SP is an 11 amino acid peptide neurotransmitter produced in sensory neurons 
that is responsible for nociception, the perception of noxious stimuli and pain 
(54). SP is transported to both the peripheral and central nerve terminals stored 
in vesicles. Depolarization of the neuron through noxious stimuli like acid, heat, 
LPS, or pro-inflammatory cytokines causes release of SP into the tissues where 
it binds to the neurokinin-1 receptor (NK-1 R) (77, 98). NK-1 R is present on mast 
cells, vascular endothelium, macrophages, and neutrophils. In the presence of 
other inflammatory stimuli , SP binding will cause acute vasodilation , histamine 
release, pro-inflammatory cytokine production, and neutrophil recruitment. 
Interestingly, in the absence of other inflammatory stimuli (LPS, tissue damage, 
etc.), SP is not sufficient to recruit neutrophils or activate macrophages (20, 92). 
It can, however, prime these cells making them more responsive to subsequent 
chemokine and LPS exposure (129). 
SP plays an important role in the inflammatory arm of neurogenic pulmonary 
edema (NPE) after brain injury. The increased efferent vagal parasympathetic 
stimulation that follows TBI can induce SP release from sensory nerve terminals 
(76, 77, 144). This causes vasodilation and inflammatory cell recruitment to the 
lung tissue already damaged by the high hydrostatic pressures following the 
catecholamine storm (1 0, 1 08). It is unclear whether SP release occurs in 
conjunction with the catecholamine storm or precedes it and primes the 
vasculature and inflammatory cells for an exaggerated response later. In an 
animal model of TBI , prior blockade of SP release prevents the extravasation of 
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fluid and inflammatory response to NPE indicating a critical role for SPin NPE 
pathophysiology (76). In stroke patients, treatment with drugs that increase 
substance P levels were shown to decrease susceptibility to pneumonia (5, 97). 
The effect of substance P on pneumonia susceptibility in TBI, where pulmonary 
substance P levels are increased, has not yet been investigated. 
Efferent Cholinergic Signaling 
The efferent arm of the vagus mediates parasympathetic control of the viscera 
and vasculature. Efferent neurons release the neurotransmitter acetylcholine that 
binds nicotinic or muscarinic acetylcholine receptors (AChRs) on smooth muscle, 
endothelium, glands, cardiac muscle, and macrophages. Macrophages express a 
specific a7 subtype of the nicotinic acetylcholine receptor (a7-nAChR) that, when 
stimulated, has profound anti-inflammatory effects (134). Kevin Tracey and co-
workers discovered the cholinergic anti-inflammatory pathway in 2000 after they 
observed vagus nerve stimulation significantly reduced the release of TN F-a by 
macrophages in response to LPS challenge (16). Further investigation revealed 
that cholinergic stimulation of macrophage a7-nAChR inhibits release of IL-1 , IL-
6, and TN F-a through c-fos mediated inhibition of NF-KB activity (119, 131, 134 ). 
This is not accompanied by an increase in IL-10 production as in catecholamine 
stimulation and allows for neutrophil recruitment and phagocytosis despite lower 
levels of pro-inflammatory cytokine production ( 128). The role of this pathway in 
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TBI has yet to be investigated in animal models but has been linked to 
suppressed inflammatory cytokine production in TBI patients (73). 
TBI and the Lung 
While neurological injury is often the primary focus of medical management of 
TBI, brain injury also has serious detrimental effects on organ systems beyond 
the central nervous system and the lungs are the most commonly affected (21, 
40, 44, 59). Respiratory dysfunction develops in up to 81% of severe TBI patients 
and is associated with significantly poorer neurological outcomes (59). The main 
causes of pulmonary dysfunction after TBI are neurogenic pulmonary edema and 
respiratory infection (59, 148, 149). 
Neurogenic Pulmonary Edema 
Neurogenic pulmonary edema (NPE) is increased extravascular fluid in the lungs 
developing at any time up to 14 days after neurological injury (124). NPE can 
occur after TBI , stroke, seizures, or even transient increases in ICP and results in 
increased vascular permeability with fluid accumulation in the alveoli and 
interstitium of the lung preventing gas exchange and causing hypoxemia (10, 47, 
1 08). Accompanying the fluid build-up is an inflammatory response that can 
damage the lung tissue and further impair respiratory function and even 
progressing to acute respiratory distress (58). Multiple factors contribute to the 
development of NPE and can be divided into hemodynamic mechanisms and 
inflammatory mechanisms. 
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Hemodynamic Mechanism 
Immediately after injury, TBI can trigger a sudden release of the catecholamines 
epinephrine and norepinephrine into the circulation from the adrenal glands 
(138). These induce vasoconstriction of the pulmonary vasculature but a 
simultaneous increase in cardiac output and blood pressure. With the heart 
pushing more blood under higher pressure into a constricted pulmonary vascular 
bed, fluid is forced into the lung tissue by hydrostatic pressure (1 0). This surged 
shift in hemodynamics is called the "blast effect" of TBI (124). While this 
mechanism may enhance the fluid shift into the airspaces, it does not explain the 
increased vascular permeability and inflammation that accompanies of NPE. 
Inflammatory Mechanism 
Inflammation is a key aspect to the initiation and progression of NPE. Pro-
inflammatory cytokines like IL-1, IL-6, and TN F-a are increased within the lung 
and the circulation in NPE and are associated with increased vascular 
permeability and inflammatory cell infiltrates that damage the lung tissue (47). 
The exact source of these cytokinesis controversial, different studies have 
implicated the brain itself, circulating and tissue monocytes, and vascular 
endothelium (50, 1 08). Direct sympathetic and parasympathetic nervous 
stimulation of the lung has also been investigated as a possible source of the 
inflammatory arm of NPE. Stimulation of either input to the lung increases 
vascular permeability and edema through the release of inflammatory 
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neuropeptides like substance P, calcitonin gene related peptide (CGRP), and 
neuropeptide Y from nerve terminals (9, 21, 76, 77, 128). 
Respiratory Infection 
Respiratory infections develop in up to 40% of hospitalized TBI patients. The 
incidence of infection increases with the severity of injury and results in longer 
hospitalizations, increased duration of mechanical ventilation, and poorer 
neurological outcomes (6, 40, 59, 70). These pneumonias are most often 
hospital-acquired (developing 48 hours or later into hospitalization) and the most 
commonly isolated organisms are Staphylococcus aureus, Pseudomonas 
aeruginosa, and Kelbsiella pneumoniae (149). Development of pneumonia after 
TBI may be due to several factors: intra-tracheal intubation and mechanical 
ventilation , aspiration of oropharyngeal bacteria while unconscious, and poor 
pulmonary toilet (55, 149). With an inoculum in the lung, alveolar macrophages 
detect and phagocytose the bacteria and release pro-inflammatory cytokines like 
IL-1 , IL-6, and TNF-a as well as the crucial neutrophil recruitment chemokine IL-8 
(MIP-2 and KC in mice) (87). Neutrophils then follow the chemotactic trail to the 
site of infection where they phagocytose bacteria, release degradative enzymes 
and reactive oxygen species, and extracellular chromatin traps to kill bacteria 
and clear them from the airspaces (87, 88). Studies in an animal model of 
ischemic stroke and pneumonia have shown deficiencies in T -lymphocyte 
function in the lung but did not investigate the innate immune response (34, 11 0). 
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The effects of TBI on the pulmonary innate immune response to pneumonia have 
not been investigated but could yield therapeutic approaches to treatment and 
prevention of pneumonia in TBI and non-TBI patients alike. 
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Chapter 2: Assessing Lung Injury in Animal Models of Traumatic Brain 
Injury and Bacterial Pneumonia 
Introduction 
After initial resuscitation, medical management of TBI is primarily focused on 
preventing deficits in neurological function. While this aspect of TBI care is 
important, respiratory dysfunction is often of lower priority. In severe TBI up to 
81% of patients experience respiratory dysfunction during their hospitalization 
making it the most common extra-neurological complication (58, 59, 148). The 
most common causes are respiratory infection and neurogenic pulmonary edema 
(1 0, 47, 55). Respiratory dysfunction results in significant excess morbidity, and 
poorer neurological outcome among TBI patients as well as longer hospital stays 
and increased healthcare costs (51, 55, 58, 59). The majority of studies have 
been directed at severe brain injury but none have looked at respiratory 
dysfunction in the much more common moderate TBI (6, 65, 81 ). Moderate TBI 
still results in axonal damage, aberrant cholinergic and adrenergic activity, and 
continuing neurological sequelae that could affect pulmonary function (51). 
Studying the consequences of traumatic brain injury requires the use of animal 
models. Replicating human TBI in an animal model has often-conflicting 
requirements. While the pattern and severity of injury must be clinically relevant 
and reproducible, it must also take into account the inherent diversity of the 
trauma patient population. The most prominent TBI models are lateral fluid 
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percussion (LFP) and weight-drop injury (WDI) (99, 145). LFP requires a small 
skin incision and craniotomy be made for placement of a fluid catheter. This 
catheter is attached to a fluid reservoir with a diaphragm that is struck with a 
weighted hammer. This transmits a fluid shock wave into the extradural space 
and compresses the brain parenchyma inducing injury (43). WDI uses a 
craniotomy to expose the extradural space and a weighted impactor is positioned 
to strike the dural surface and injure the cortex beneath it (79). While these 
models produce excellent specific injury to the brain for neurological studies, the 
skin and bone incisions required by both models cause significant immune 
reactions that could confound immunological studies (145). Therefore an injury 
model is needed that requires no incision or craniotomy. 
Acute lung injury (All) and the more severe form, acute respiratory distress 
syndrome (ARDS) can be caused by a variety of pathological processes that 
affect the lung either directly or indirectly (135). In TBI, a variety of neural 
signaling pathways are implicated in the development of All. Hemodynamic 
instability due to aberrant sympathetic stimulation and inflammation due to 
tachykinin release have been shown to contribute to the development of NPE 
after TBI while anti-inflammatory sympathetic and parasympathetic signaling are 
thought to predispose TBI patients to nosocomial pneumonia (1 0, 36, 71, 108, 
111, 140). Previous work in a mouse model of stroke demonstrated brain 
infarction induced both lung injury and the development of spontaneous 
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pneumonia (110). Our study seeks to investigate the development of All 
following moderate TBI from both of these mechanisms. 
As a positive control for lung injury, we needed a mouse model of nosocomial 
pneumonia. P. aeruginosa is a common cause of gram-negative nosocomial 
pneumonia (136) capable of causing severe or fatal infections (46). Previous 
experimental studies show that P. aeruginosa leads to the development of All, 
characterized by substantial alveolar protein-rich edema (12). The recruitment of 
airway neutrophils is a also major component of the initial host immune response 
to P. aeruginosa (88). Multiple cytokines that regulate host lung defense and 
inflammation are increased during this bacterial infection. A variety of 
histological abnormalities are seen in the lung including fibrinous exudate, 
polymorphonuclear leukocytes, hemorrhage, and alveolar septal necrosis (142). 
Impaired oxygenation may significantly affect pulmonary physiology and survival 
in P. aeruginosa infection. 
In our study, lung function and histological characteristics of TBI mice and 
pneumonia mice were obtained to evaluate for the presence of pulmonary injury. 
Since inflammation may occur without injury, several parameters of pulmonary 
inflammation were also analyzed. TBI mice were sampled and sacrificed at 48 
hours, the point at which respiratory dysfunction most commonly develops in 
human TBI patients while pneumonia mice were similarly analyzed 18 hours after 
bacterial challenge (58). 
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Methods 
Animals 
Female ICR mice (Harlan-Sprague Dawley, Indianapolis, IN) were used for all 
experiments. All mice were 8-10 weeks of age, weighed 24-30 grams, and were 
housed for at least 3 days prior to use with a 12 hour light/dark cycle. Food and 
water were provided ad-libitum throughout the studies. All experiments were 
approved by the Institutional Animal Care and Use Committees of Boston 
University. 
TBI Model 
lsofluorane anesthetized animals are positioned on a foam-padded platform 
underneath the impactor rod with the point of impact located in the midline, 
halfway between the interauricular and interorbital lines overlying the frontal 
lobes. Once positioned, the rod is raised 7 em and released, producing 
approximately 5 kg/cm2 of impact force . A felt pad on the end of the impactor 
prevents rebound impacts and damage to the overlying tissues. Immediately 
after impact, animals receive an injection of buprenorphine and are allowed to 
recover on a warming bed until capable of righting themselves from a supine 
position at which point they are returned to their cage. Sham injury animals 
undergo the same procedure but the impactor is not dropped. TBI animals 
require 5 to 1 0 minutes of recovery before they are able to right themselves as 
opposed to 30-45 seconds in sham animals. 
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Pneumonia Model 
Pneumonia was induced by anesthetizing 8 mice with isoflurane and 
administering 5x107 CFU of Pseudomonas aeruginosa (ATCC strain Boston 
41501) in 50 microliters of Hank's balanced salt solution via hypopharyngeal 
administration as previously described (48). A group of 8 mice received 50ul 
normal saline as a negative control. Eighteen hours later all mice were sacrificed 
for further analysis. 
Whole body plethysmography 
Respiratory parameters were measured using a whole body plethysmography 
system (Buxco Research Systems, Wilmington, NC) prior to TBI or sham injury 
and repeated at 4, 24, and 48 hours after injury. Measurements included 
respiratory rate, tidal volume, time of inspiration and expiration, and peak 
inspiratory and expiratory flow. Mice were individually placed into the chamber of 
the plethysmograph and left to acclimate for 10 minutes as previously described 
(56). Mice were conscious and unrestrained, and they showed normal 
exploratory behavior. Respiratory measurements were also collected at baseline 
and 18 hours after intervention for mice receiving normal saline or P. aeruginosa. 
Blood and Lung Sampling 
At 4, 24, and 48 hours post TBI or sham injury, 20 !JI of blood was collected by 
facial vein puncture as previously described (27) for a complete blood count with 
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differential using a Hemavet instrument (CDC Technologies, Oxford, CT). 
Following whole body plethysmography measurements at 48 hours, the mice 
were anesthetized with a solution of 87 j..Jg/g Ketamine and 13 j..Jg/g Xylazine in 
normal saline. Mice receiving P. aeruginosa or normal saline IT were sacrificed 
after 18 hours. Blood was collected by carotid artery cutdown in both groups. 
Arterial Blood Gas 
48 hours after TBI or sham injury or 18 hours after administration of P. 
aeruginosa or normal saline, mice were anesthetized as described above. Using 
a dissecting microscope, a midline ventral neck incision was made from the 
mandible to sternal notch. The fascia and strap muscles were bluntly dissected 
until the carotid artery was exposed, and it was clamped distally to engorge the 
vessel with blood. The carotid artery was punctured with a 30G heparin rinsed 
syringe and 100uL blood was collected for arterial blood gas (ABG). An iSTAT 
analyzer (Abbott Laboratories, Princeton, NJ) with CG4+ cartridges was used for 
ABG measurement and arterial oxygen saturation. The remainder of the blood 
volume was collected in a separate syringe and mixed with SOuL of 169mM 
EDT A. 
Single lung bronchoalveolar lavage (BAL) 
The thorax was opened with a midline incision through the sternum to expose the 
heart and lungs. The left lung hilum was clamped closed. Right-sided BAL was 
performed by exposing the trachea and cannulating it with a polyethylene 
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catheter and then the right lung was lavaged with a total of 2.5ml of warm 
Hanks' Balanced Salt Solution (HBSS, Mediatech, Inc., Herndon, VA). 100ul of 
the first O.Sml was serially diluted for bacterial colony forming units. The 
remaining 400ul and two subsequent 1 ml aliquots were centrifuged separately 
and the supernatant from the first wash was stored at -ao·c for later 
measurement of cytokines. Bacterial counts in BAL fluids and lung homogenates 
were determined 12 hours after samples were plated in triplicate on sheep blood 
agar plates. The supernatant from the second wash was discarded and the 3 
pellets were resuspended in HBSS and combined. A total cell count was 
performed with a Beckman-Coulter particle counter model ZF (Coulter 
Electronics Inc., Hialeah, FL) and a differential count was obtained by counting 
300 cells on cytospin slides stained with Diff-Quick (Baxter, Detroit, Ml). 
Following lavage, the right hilum was clamped and tied off distally with 4-0 silk. 
The right lower lobe was used to determine the wet/dry ratio and the remainder 
of the right lung was stored for the myeloperoxidase assay. Next, a syringe filled 
with 10% buffered formalin at 25 em water pressure was connected to the 
tracheal catheter and the left lung clamp was released to insufflate the lung for 2 
minutes. The left lung was removed and placed into 10% formalin for fixation 
and histological analysis. 
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Histopathology 
Formalin fixed lung and brain tissue was embedded in paraffin and sectioned at 5 
J.Jm for routine histology. Slides were stained with hematoxylin and eosin and 
edema, hyperemia, congestion, neutrophil margination and tissue infiltration, 
were evaluated to establish the presence or absence of lung injury as previously 
described (8). 
Myeloperoxidase assay 
The myeloperoxidase (MPO) assay was performed as previously described 
(123). 
Enzyme-linked immunosorbent assay 
An aliquot of the 1 : 1 0 diluted plasma collected at 24 hours from all the mice was 
used to determine the IL-6 concentration by ELISA as previously described (95). 
A separate plasma aliquot was stored and used to measure a variety of pro and 
anti-inflammatory cytokines using the sequential ELISA technique (102). This 
analysis was also performed on the supernatant of the BAL fluid. 
Statistical Analysis 
Column analysis was performed using two-tailed T -tests. Serial measures were 
analyzed using 2-way ANOVA with Bonferroni post- hoc test to determine 
significance between groups. 
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Results 
Post-Injury Animal Coma Scale 
To model human moderate TBI in mice, we needed an injury assessment scale 
to ensure that our model produced a consistent injury with similar neurological 
findings between animals. The human Glasgow Coma Scale (GCS) served as a 
basis for our scale with modifications to make it relevant for animals (63). Our 
modifications are noted in table 1. Mice were evaluated after returning to sternal 
recumbence following injury. As moderate TBI corresponds to a score of 9-12 in 
the human GCS, we only used mice that scored in that range on our mouse 
modified coma scale (MMCS) and showed no signs of focal neurological deficit 
(paralysis, side neglect, deviation to one side). These would be assessed in mice 
that had righted themselves to sternal recumbency for at least two minutes after 
anesthesia had worn off. 
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Table 1: Human Glasgow coma scale and mouse modified coma scale. Mice were evaluated on 
observed resting posture, response to sound (snapping fingers by each ear), and response to 
being lifted and suspended by the tail. 
Human Glasgow Coma Scale Mouse Modified Coma Scale 
Spontaneous 4 MovinQ about caQe 4 
Eye To command 3 Hunched 3 Posture Opening To pain 2 Dazed sternal recumbence 2 
None 1 Prone 1 
Oriented 5 Turns to investiQate 5 
Confused, 4 4 disoriented Moves awav 
Verbal Inappropriate words 3 Response to Startle 3 Response Sound 
Incomprehensible 
sounds 2 Wincina (no body movement) 2 
None 1 No response 1 
Obeys commands 6 Extension and reachinQ 6 
Localizes pain 5 Extension without reachinQ 5 
Withdraws 4 Lifts head flexion 4 
Motor Abnormal flexion to Tail Lift 
Response pain 3 Response Flexion no head lift 3 
Abnormal extension 2 2 to pain Deviates to one side 
None 1 No response 1 
Best total score 15 15 
As our goal was to study the immunological consequences of TBI, we needed a 
mouse model of injury that would reflect the types of injuries sustained in mild to 
moderate TBI patients without confounding immune responses due to skin 
incisions or craniotomy. The mice also needed to be injured to a level that 
produced a measurable physiological effect but did not render them comatose or 
in need of ventilation . An impact force had to be chosen that would result in gross 
brain parenchymal damage without depressed skull fracture or lethal spreading 
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hematoma. For these reasons we chose to use a modified weight-drop injury 
model (79). We constructed a device consisting of a 180 gram steel rod that 
slides with minimal friction through a guide sleeve supported in a ring stand 
(Figure 1A). The rod was raised to different heights to achieve higher or lower 
impact force as needed. Impact was calibrated using a suspended scale with a 
deadfall needle that registers peak force. 
Figure 1: Weight drop injury device. A) Device with animal platform removed . B and C) views 
from above and side of animal positioning. Note neck restraint to limit extraneous motion and 
maintain consistent head position. 
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Trials in live and dead animals found that an impact of about 5 kg/cm2 force 
(impactor released from 7 em height) generated the ideal level of both 
pathological injury and neurological impairment (MMCS -12-9, table 1) in 90% of 
the mice. The other 10% were more impaired, died, or displayed focal 
neurological deficit and were excluded from further study. Formalin-fixed brains 
from TBI mice were examined for gross and microscopic injury (Figure 2). Injury 
was found to be confined to the inferior surface of the frontal and temporal lobes 
and consisted of intraparenchymal bleeding surrounding the middle cerebral and 
striate vessels. This is consistent with a combination of contracoup and skull-
base gliding contusions seen in frontal impacts in humans (133, 137). 
The location of the injuries caused by this model has some definite effects on 
mouse behavior and physiology assessed by the MMCS. The area injured 
contains the optic nerves and chiasm, the hypothalamus, amygdala, and other 
elements of the limbic system. Damage to these areas could impair visual 
function and the fear response, both of which would change the mouse posture 
and responses to sound and tail-lift (53, 64 ). Damage to the hypothalamus could 
change thermal regulation and the fever response which could alter both immune 
function and the general illness behavior of the mouse (64). We did note 
aggressive behavior in the mice after injury with a hunched defensive posture 
and sensitivity to sound and physical stimulus. 
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Figure 2: Pattern of injury 24 hours after modified weight drop injury TBI. Cerebral contusions bilaterally on the inferior 
surface of the frontal and temporal lobes corresponding to a contracoup and skull floor washerboard injury mechanism. 
A) Gross image of inferior surface. B) Frontal section through injury magnified 4X. C) Same section magnified 1 OX 
Acute Immunological Impact of TBI 
Complete blood count and cytokine analysis were performed on samples 
collected from TBI and sham mice by facial vein bleed (Figure 3). TBI mice had a 
significant increase in blood neutrophils 4 hours after injury and a decrease in 
blood lymphocytes. These changes did not affect the total white blood count and 
both returned to baseline by 24 hours (Figure 3A). The plasma cytokines IL-6, IL-
1 ra, and MIP-2 followed a similar pattern and returned to baseline by 48 hours 
(Figure 38). Interestingly, IL-10 levels were below the limit of detection (0.09868 
ng/ml) in the plasma of TBI mice (data not shown) which is contrary to current 
literature describing increased IL-10 levels following TBI (138). We also did not 
see the prolonged drop in lymphocyte counts described in previous studies (111, 
112). 
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Figure 3: Blood cell counts (A) and plasma cytokines (B) in TBI and sham injury animals 4, 24, 
and 48 hours after injury. TBI mice have increases in neutrophil counts accompanied by transient 
rises in inflammatory cytokines and a transient fall in lymphocyte count. *p<0.05 TBI vs sham 
Bonferroni post-hoc test. 
Respiratory Physiology 
Physiological respiratory parameters were measured using whole body 
plethysmography and the values obtained prior to injury for the mice undergoing 
TBI as well as values for the sham mice were within published normal ranges for 
all the parameters measured (130). TBI mice demonstrated significant decreases 
in respiratory rate accompanied by increases in time of inspiration and expiration 
(Figure 4 ). This is in keeping with respiratory depression seen in other models of 
moderate brain injury (6, 79, 1 09). By 24 hours these values had returned to 
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match those of sham animals with the exception of a transient decrease in tidal 
volume. 
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Figure 4: TBI transiently depresses respiration. Buxco WBP at baseline and 4, 24, and 48 hours 
post TBI or sham injury demonstrating decreased respiratory rate and increased times of 
expiration and inspiration. *p<0.05 TBI vs sham Bonferroni post-hoc test. 
Intra-tracheal pneumonia challenge in non-TBI mice resulted in significant 
decreases in respiratory rate and tidal volume while increasing times of 
inspiration and expiration (Figure 5). These changes are similar to those seen in 
the TBI m_ice at the 4 hour time point but in pneumonia or lung injury, these 
changes are due to airway obstruction and increased work of breathing as 
evidenced by the decreased tidal volume. This differs from the direct brainstem-
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mediated slowing of respiratory rate seen in TBI without accompanying changes 
in tidal volume (6, 79). 
Respiratory Rate Tidal Volume 
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Figure 5: Bacterial pneumonia causes significant disturbances in respiratory function . Buxco WBP 
data 18 hours after IT administration of normal saline or 5x1 07 CFU of P. aeruginosa. *p<0.05 
Hypoxemia 
The most important pulmonary function is performing the gas exchange 
necessary for maintaining the supply of 02 to the tissues and eliminating C02. 
Arterial oxygen saturation was measured from the carotid artery of mice 
immediately prior to sacrifice at 48 hours in mice subjected to TBI or sham injury 
and at 18 hours for non-TBI mice receiving P. aeruginosa or normal saline. As 
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seen in Figure 6, the arterial oxygen saturation was maintained in TBI mice and 
was no different compared to normal saline controls, but gas exchange was 
markedly impaired in mice with bacterial pneumonia. Maintenance of a normal 
arterial oxygen saturation indicates that TBI mice do not develop hypoxemia. 
Arterial Oxygen Saturation 
c 
0 
:.;:::: 
«< 
.... 
::I 
-«< Ill 
N 
0 
Sham TBI Normal Saline Bacteria 
Figure 6: Pneumonia but not TBI results in decreased arterial oxygen saturation. Arterial oxygen 
saturation obtained by carotid cutdown and ABG 48 hours after TBI or sham injury and 18 hours 
after IT administration of normal saline or 5x107 CFU of P. aeruginosa. *p<0.05 
Spontaneous Pneumonia 
Previous studies in a mouse model of ischemic stroke had demonstrated the 
development of spontaneous pneumonia after ischemic injury to the brain (110). 
As the pathology demonstrated in the brains of our TBI mice could result in 
ischemic damage, we assessed the presence of spontaneous pneumonia in our 
TBI mice using the pneumonia animals as a positive control (137). We cultured 
samples of BAL supernatant and lung homogenate from these animals for 
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bacterial growth. The pneumonia mice had high levels of recoverable bacteria in 
both BAL and homogenate as expected but our TBI mice failed to demonstrate 
any bacteria (Figure 7). This indicates that our moderate brain injury does not 
result in the development of spontaneous pneumonia. 
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Figure 7: TBI does not result in spontaneous pneumonia. Lung homogenate and BAL supernatant 
bacterial counts demonstrating bacterial growth only in pneumonia positive control mice. BDL-
below detection limit 
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Lung Damage 
Accumulation of neutrophils in the lungs may cause severe degradation of the 
lung tissue through release of proteases and formation of reactive oxygen 
species (8, 127). To determine their presence in the alveolar space, lung 
parenchyma and circulation , neutrophil counts were measured in sacrificed mice. 
Photomicrographs of representative cytospin slides demonstrate only alveolar 
macrophages in BAL recovered from TBI, sham, and normal saline mice (Figure 
8 A,B,C). In contrast, bacterial pneumonia (Figure 8 D) showed a predominance 
of neutrophils with an increase in red blood cells. Quantitatively, BAL fluid at 48 
hours after TBI showed no influx of neutrophils in the airways (Figure 8 E) versus 
bacteria. Additionally, there were similar numbers of alveolar macrophages in all 
mice sampled (Figure 8 F). 
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Figure 8: TBI does not induce significant cell recruitment to the airways. Representative cytospins 
(A-D) and differential counts (E and F) of cells recovered by BALin sham , TBI , normal saline, and 
pneumonia mice respectively. 
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Myeloperoxidase Assay 
Myeloperoxidase (MPO) is frequently used to measure the presence of 
neutrophils in tissues (2, 96). MPO activity did not increase in TBI mice 
compared to sham or normal saline (Figure 9). However, non-TBI mice receiving 
bacteria had a significant increase in lung MPO compared to the non-TBI normal 
saline control. The data presented in figures 5 and 6 indicates that there is no 
significant recruitment of neutrophils to the lungs of the TBI mice that could lead 
to lung injury. 
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Figure 9: TBI does not result in neutrophil recruitment to the lung. Myeloperoxidase activity in 
lung homogenates from TBI and sham mice 48 hours after injury and mice 18 hours after 
receiving IT administration of normal saline or 5x107 CFU of P. aeruginosa. 
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Lung Histopathology 
To confirm the lack of neutrophil recruitment and edema formation in the lungs of 
the TBI mice, microscopic examination of H&E stained lung sections from all 
groups was performed. Figure 10 shows representative images from 48 hour TBI 
and sham injury, as well as a mouse given normal saline or bacteria. There were 
no visible neutrophils in the alveoli and interstitial spaces of either the TBI or 
sham mice confirming the results from the BAL cytospin slides. No indication of 
protein leakage into the alveolar space was found with no detection of hyaline 
substance accumulation or edema fluid but TBI mouse lungs did demonstrate 
some dilated blood vessels and hyperemia. Conversely, mice given bacteria 
exhibited significant edema, hyperemia, congestion, neutrophil margination and 
infiltration, hemorrhage, and the presence of debris. All of these parameters 
demonstrate that there is no significant lung injury 48 hours after moderate TBI. 
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Figure 10: TBI does not result in histologically evident lung injury. Representative microscopic 
images of sectioned lungs from sham , TBI, normal saline, and pneumonia mice at 10, 20, and 
40X magnification. NS- normal saline IT, PA-P. aeruginosa IT. 
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Lung Inflammation 
Finally, the presence of pulmonary inflammatory mediators was tested by 
measuring the local concentration of cytokines in the BAL fluid of the mice 
sacrificed at 48 hours. The BAL fluid concentration of 5 cytokines including IL-6, 
KC, MIP-2, TN F-a, and IL-1 ra was similar in the TBI, sham, and normal saline 
mice as seen in Figure 11. Importantly, the bacterial pneumonia caused a 
significant increase in each of the BAL cytokines. These results indicate TBI does 
not induce inflammatory cytokine production in the airways corresponding to lung 
injury. 
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Figure 11 : Pneumonia but not TBI induces inflammatory cytokine production in the lung. Cytokine 
levels in BAL supernatants of mice 48 hours post TBI or sham injury and 18 hours after IT 
administration of normal saline or 5x107 CFU of P. aeruginosa. 
39 
Discussion 
The development of respiratory dysfunction following TBI is a serious clinical 
problem that can affect the management and outcome of brain injured patients. 
To date, no clinical or basic science studies have investigated respiratory 
function in moderate TBI. In this study we have shown that our mouse model of 
moderate traumatic brain injury produces a consistent and clinically relevant level 
of brain injury without invasive manipulation. This level of brain injury does not 
result in lung injury through neurogenic pulmonary edema or development of 
spontaneous pneumonia as determined through detailed analysis of lung function 
and pathology. Our model of P. aeruginosa pneumonia did cause significant lung 
injury that was well-demonstrated by our analytical parameters and served as an 
appropriate positive control. 
Many animal models of TBI require invasive measures like craniotomy to ensure 
a reproducible injury pattern. While they may generate a specific injury, the 
mechanism is not as clinically relevant to the brain injury population as closed 
head injury (145). Our model replicates a commonly encountered mechanism of 
injury (impact acceleration) and reproducibly induces cerebral contusions in a 
pattern seen in frontal impacts (57). The level of neurological deficit following 
injury, when assessed with a modified coma scale, is consistent with those seen 
in moderate TBI patients. A limitation of our model is the severity of parenchymal 
injury. To induce more severe injury, the impact required would result in a skull 
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fracture that would both confound our immunological parameters and most likely 
result in the death of the animal. 
Hematological changes following TBI have been well-documented in the basic 
science literature and showed marked immunosuppression with sustained drops 
in blood lymphocytes and inflammatory cytokine production (111 ). While we did 
see a brief decrease in lymphocytes, they returned to normal levels by 24 hours 
after injury and most likely represented the well-documented apoptosis that 
follows a traumatic injury (67). Inflammatory cytokine production did not seem to 
be impaired as we did see a brief spike in IL-6, MIP-2, and IL-1 ra production after 
TBI. Importantly we did not detect an increase in IL-10 at any point in our TBI 
animals which has been suggested to cause lymphocyte apoptosis and 
decreased inflammatory cytokine production after TBI (113, 138, 140). This may 
be due to the lesser severity of our injury model. 
Severe brain injury has been shown to result in lung injury through neurogenic 
pulmonary edema and bacterial pneumonia in animal models and humans (55, 
59, 149). In our model we did not find evidence of either mechanism of injury. We 
did observe a brief decrease in respiratory function immediately after TBI with 
plethysmography. These results were consistent with respiratory depression 
seen in human and animal TBI mediated by brainstem respiratory centers rather 
than impaired mechanics of respiration from airway inflammation (31, 130, 147). 
These parameters returned to baseline levels by 24 hours and gas exchange 
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was not affected. A more severe injury might induce more hemodynamic shifts to 
induce the hydrostatic damage of lung vasculature with subsequent inflammatory 
response due to neural inputs. Interestingly we did see histological evidence of 
hyperemia and vasodilation in TBI mouse lungs. This may represent tachykinin 
release into the lungs after TBI (5, 36, 76). Our injury may cause low level 
substance P release that, in the absence of hydrostatic tissue damage or 
infection, will induce vasodilation of pulmonary vasculature without edema or 
recruitment of inflammatory cells. 
We did not recover any bacteria from the lungs of our TBI mice and the cytokine 
and cell recruitment profiles did not reflect infection especially when compared to 
our pneumonia positive control. This does not mean that the pulmonary immune 
response to infection will not be altered by TBI and could be explained by better 
respiratory toilet when compared to the more severe models of injury that found 
spontaneous pneumonia (110). Further investigation with bacterial challenge of 
TBI mice will be required to elucidate any effects on the pulmonary immune 
response to pneumonia that may follow TBI and increase susceptibility to 
infection. 
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Chapter 3: Traumatic Brain Injury Enhances Resistance to Bacterial 
Pneumonia 
Introduction 
Traumatic brain injury (TBI) is a major cause of death and disability in both in 
civilian and military trauma patients. While early mortality is primarily attributed to 
non-survivable head injury, delayed deaths following head injury are often 
secondary to non-neurologic organ dysfunction as a result of infectious and 
inflammatory processes. Pneumonia is the most common infectious 
complication associated with TBI, occurring in 20-60% of head injured patients, 
rates that are thought to be increased compared to non-head injured patients 
(55, 58). Risk factors for the development of pneumonia after TBI include post-
injury immunosuppression and prolonged mechanical ventilation (19). 
Immunosuppression after TBI has been demonstrated predominantly via a 
decline in the adaptive immune system (86). CD4 and CD8 cell types are 
decreased after TBI for a prolonged period of time (111 , 138, 140). However, 
both adaptive and innate immunity both play important roles in controlling 
infection. Neutrophils and macrophages of the innate immune system are vital 
for appropriate bacterial clearance. Neutrophil recruitment is regulated by 
multiple factors, including CXCR2 chemokines KC and MIP-2, leukotrienes, and 
substance P (28, 80). Enhanced recruitment of neutrophils to a site of infection 
has been shown to significantly improve bacterial clearance and survival (27). 
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In the present study, we sought to determine the relationship between TBI and 
pulmonary infection. Our unexpected results indicate that patients suffering TBI 
have significantly lower rates of pneumonia than non-head injured trauma 
patients. However, this observation was only found using propensity score 
matching, underlining the importance of appropriate data analysis. Our clinical 
data is supported by an animal model of TBI and P. aeruginosa pneumonia. We 
found TBI mice had improved survival following bacterial challenge compared to 
sham injury animals. TBI mice demonstrated increased neutrophil recruitment to 
the airspaces in the acute phase of pneumonia which is critical for increased 
bacterial clearance and reduced pneumonia morbidity and mortality 
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Methods 
National Trauma Data Bank 
The National Trauma Data Bank 7.2 (NTDB; American College of Surgeons) was 
queried to investigate the clinical association between TBI and pneumonia. The 
analysis for this study was from the most recently updated data, reporting 
hospital admissions for 2010. Our study included patients with a hospital length 
of stay longer than two days, an age greater than 18 at admission, and a blunt 
mechanism of injury. 
Data was analyzed for patients with blunt traumatic injuries and those with 
traumatic brain injuries, with identification of the frequency of pneumonia as a 
complication. Head injured patients were identified as those individuals with at 
least one ICD-9 code consistent with traumatic brain injury. These individuals 
were further grouped, using the Glasgow Coma Score (GCS), into mild (13-15), 
moderate (9-12), and severe (<9) TBI categories. The blunt traumatic injury 
group consisted of patients whose diagnosis codes did not include either a head 
or neck injury. 
Demographics, baseline vital signs, injury severity score, length of stay, and 
requirement for mechanical ventilation were summarized descriptively and 
analyzed statistically using SAS Version 9.3. Because of the significant 
differences observed in the demographic and vital signs data (Table 1 ), and the 
potential impact of these differences on incidence of pneumonia, propensity 
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scoring was used to more precisely match each TBI cohort to the blunt trauma 
cohort. Propensity scores were generated using multivariate logistic regression 
with group membership as the dependent variables and a variety of baseline 
variables, their squares, and interactions as explanatory variables. In all 
matched data, patients with chest injuries were excluded due to the synergistic 
factors contributing to the development of pneumonia. 
Animals 
Female ICR mice (Harlan-Sprague Dawley, Indianapolis, IN) were used for all 
experiments. All mice were 8-10 weeks of age, weighed 24-30 grams, and were 
housed for at least 3 days prior to use with a 12 hour light/dark cycle. Food and 
water were provided ad-libitum throughout the studies. All experiments were 
approved by the Institutional Animal Care and Use Committees of Boston 
University. 
Murine Models of Moderate TBI and Pneumonia 
Under isofluorane anesthesia, mice were placed in a prone position on a 
plexiglass bed with their head resting on a foam pad under a weight drop impact 
device. To induce the TBI, a 170 gram steel rod within a guide tube was released 
from 5.2cm to a point in the midline, halfway between the interauricular and 
interorbital lines, producing approximately 5 kg/cm2 of impact force. Rebound 
impact was prevented and the mouse was immediately removed from the device 
and given an i.p. injection of 0.05mg/kg buprenorphine in 1 ml of normal saline. 
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Mice are placed supine on a warming bed and returned their cages after righting 
themselves to sternal recumbence. Sham mice underwent similar sedation and 
' 
analgesia without TBI. 
P. aeruginosa Pneumonia 
Pneumonia was induced 48 hours post-TBI by anesthetizing mice with isoflurane 
and administering 1x107 CFU or 5x107 CFU of Pseudomonas aeruginosa (ATCC 
strain Boston 41501) in 50 ul of Hank's balanced salt solution via 
hypopharyngeal administration (48). Mice were allowed to recover and were 
monitored for up to 7 days. An additional group of animals was sacrificed four 
hours after infection to obtain pulmonary bacterial loads by bronchoalveolar 
lavage (BAL) and lung homogenates. 
Whole Body Plethysmography 
Respiratory parameters were analyzed as described in chapter 2 at baseline, 4, 
8, 24, and 48 hours after bacterial challenge. All were compared to a group of 
mice 48 hours post TBI with no pneumonia. 
Plasma and Tissue Analysis 
Plasma samples were obtained by cardiac puncture at the time of sacrifice under 
ketamine/xylazine anesthesia. To determine whether this increased bacterial 
clearance was due to local cell recruitment, we analyzed the cellular content of 
the BAL fluid . BAL was performed with Sml of warm Hank's balanced salt 
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solution (HBSS) in 1 ml aliquots. 1 001JI of the first aliquot was retained for 
bacterial count. The supernatant from the remainder of the first aliquot was used 
for cytokine analysis. The cell pellets of all aliquots were combined and counted 
using a Beckman Coulter particle counter (Coulter Electronics, Danver, MA). 
Differential counts of these cells were performed by counting 300 cells on 
cytospin slides stained with Diff-Quick (Baxter, Detroit, Ml). After lavage, the 
lungs were sterilely transferred to 3ml of HBSS and homogenized. Bacterial 
counts in BAL fluids and lung homogenates were determined 24 hours after 
samples were plated in triplicate on sheep blood agar plates. Cytokines and 
chemokines (IFN-y, IL-1 ra, IL-6, IL-1 0, KG, MIP-2, TN F-a) were measured by 
sandwich ELISA using matched antibody pairs (R&D Systems) (95). 
Statistical Analyses 
The predicted probabilities of group membership among the patients (propensity 
scores) in conjunction with a SAS 1:1 matching macro were used to create 
matched comparison groups. The groups were then compared using chi-square 
and rank-sum statistics to gauge whether any residual differences remained. 
Survival studies were analyzed with Kaplan-Meier analysis. Other analyses were 
completed with T -tests. Serial measures were analyzed using 2-way AN OVA 
with Bonferroni post- hoc test to determine significance between groupsat each 
time point. 
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Results 
Unadjusted NTDB Data Shows Increased Pneumonia Rates in TBI Patients 
The NTDB for the year of 2010 included a total population of 722,836 patients. 
Table 1 shows demographic and arrival vital signs data for 209,056 patients 
included in our control cohort, blunt trauma patients without head or neck injuries, 
as well as 56,528 patients with a blunt trauma and TBI. Statistical differences 
were found in all demographic variables analyzed. 
Table 1. Demographics of all blunt traumatic injuries and traumatic brain injuries in the National 
Trauma Database for 2010. Excluded were patients in the hospital for <2 days and <18 years of 
age. 
Blunt Trauma Blunt Trauma 
w/o TBI w/TBI 
Variable (n=208,993) (n=56,528) pValue 
Sex, male,% 56 64.5 < 0.0001 
Mean± SO 
Patient age 56.2 ± 21.1 52.5 ± 21.3 < 0.0001 
ISS 9.8± 7.2 16.6± 9.8 < 0.0001 
Temperature 36.4± 2.0 36.4± 1.8 0.0107 
Systolic Blood Pressure 140.8± 27 .0 140.7±28.3 0.48 
Heart Rate 86.5± 19.0 89.9± 20.9 < 0.0001 
Median (interquartile range) 
ICU Length of stay, days 0 (0-2) 2 (0-4) < 0.0001 
Hospital Length of stay, days 5 (4-8) 6 (4-10) < 0.0001 
The TBI patients were further divided into mild, moderate, and severe TBI to 
evaluate rates of pneumonia. The incidence of pneumonia in control, mild, 
moderate, and severe TBI groups is shown in Figure 1. While patients with mild 
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TBI had a similar incidence of pneumonia as controls, patients with moderate TBI 
had a higher incidence of pneumonia than either of these groups. Furthermore, 
patients with severe TBI had a significantly higher incidence of pneumonia 
compared to all three other groups. 
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Figure 1: Incidence of pneumonia from the National Trauma Database for 2010 for blunt 
traumatic injuries (n=209,056), mild TBI (n=42,802), moderate TBI (n=3, 163), and severe TBI 
(n=8,285). Blunt traumatic injuries have a rate of pneumonia of 3.3%, mild 3.4%, moderate 
10.3%, and severe 19.7%. *p<0.05 
Because mechanical ventilation is a primary risk factor for acquiring pneumonia, 
we evaluated the number of patients in each group requiring mechanical 
ventilation, and the relationship of duration of time on the ventilator with 
incidence of pneumonia. Whereas 10.5% of the control blunt injury cohort 
required mechanical ventilation, 25.2% of all TBI patients required mechanical 
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ventilation . Not surprisingly, the mechanical ventilation needs of head injured 
patients increased with injury severity, with 12.1% of mild, 48.2% of moderate, 
and 85.3% of severe TBI patients requiring mechanical ventilation. The 
relationship between the time on the ventilator and incidence of pneumonia was 
examined. As expected, the rate of pneumonia increased with greater time spent 
on mechanical ventilation in each group (Table 2). 
Table 2. The incidence of pneumonia in blunt traumatic injury, mild TBI, moderate TBI , and 
severe TBI for patients ventilated for 1-5 days, 6-15 days, 16-30 days, or >30 days. 
Rate of Pneumonia In patients (%) 
Total Ventilator Days Control MildTBI Moderate TBI SevereTBI 
1-5 Days 7.45 7.33 5.73 6.19 
6-15 Days 33.6 31.09 30.14 32.29 
16-30 Days 49.98 45.97 49 .33 49.26 
> 30 days 60.25 61.81 50 56.85 
Propensity Score Matching Demonstrates That TBI Patients Have 
Significantly Lower Risk of Pneumonia 
Patients were divided into subgroups for propensity score analysis based on 
need for mechanical ventilation. Patients were then matched based on age, 
injury severity score, admission heart rate, respiratory rate, systolic blood 
pressure, and temperature. Demographic and vital signs data for these groups 
are shown Table 3a and b. While there were no differences in injury severity 
score or admission vital signs amongst ventilated patients, other parameters 
including number of days on mechanical ventilation reached statistical 
significance. 
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Table 3. A.) Demographics for control and mild TBI requiring mechanical ventilation matched with 
propensity scoring. n=2311. B.) Demographics for control and moderate TBI requiring 
mechanical ventilation matched with propensity scoring. n=694. C.) Demographics for control 
and severe TBI requiring mechanical ventilation matched with propensity scoring. n=2524 
A. Control MlldTBI Variable (n=2311) (n=2311) pValue 
Age 56.1± 20.3 57.0± 20.6 0.11 
Sex, male 72.48% 69.67% 0.035 
ISS 17.9 ± 8.3 17.6±8.4 0.32 
Heart rate 89.9± 23.3 90.0± 21.6 0.92 
Respiratory Rate 19.4± 6.4 19.2 ± 4.5 0.4 
Systolic Blood Pressure 143.7 ± 29.5 144.5 ± 29.4 0.32 
Temperature 36.3± 1.5 36.3± 2.1 0.28 
Ventilator days 3 (2-9) 3 (1-8) 0.007 
ICU days 6 (3-12) 6 (3-12) 0.68 
Hospital length of stay 11 (6-20) 11 (6-20) 0.81 
B. Control Moderate TBI Variable (n=694) (n=694) pValue 
Age 49.6± 19.8 50.3± 20.3 0.54 
Sex, male 71.76% 70.03% 0.48 
ISS 17.9±8.5 17.6±8.9 0.53 
Heart rate 92.9± 24.9 93.8± 24.0 0.48 
Respiratory Rate 18.4± 7.5 18.7 ± 6.3 0.39 
Systolic Blood Pressure 142.0± 30.3 146.9±33.4 0.34 
Temperature 36.2 ± 1.6 36.1± 2.8 0.51 
Ventilator days 4 (2-10) 3 (1-8) 0 .017 
ICU days 6 (3-12) 5 (3-11) 0.1 
Hospital length of stay 11 (6-20) 10 (5-19) 0 .014 
C. Control SevereTBI Variable (n=2524) (n=2524) pValue 
Age 45.0± 19.4 45.4± 19.6 0.55 
Sex, male 75.40% 74.37% 0.4 
ISS 18.2± 9.3 18.2± 9.3 0.87 
Heart rate 96.0± 24.8 95.4± 24.2 0.43 
Respiratory Rate 12.5± 8.8 12.2± 9.3 0.16 
Systolic Blood Pressure 143.4± 32.2 143.8± 31.4 0.87 
Temperature 36.1± 2.6 36.1 ± 2.7 0.73 
Ventilator days 3 (1-9) 3 (2-8) < 0.0001 
ICU days 5 (3-12) 5 (3-11) 0.061 
Hospital length of stay 11 (6-20) 10 (5-18) 0.047 
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Analysis of pneumonia incidence rates in matched cohorts of ventilated patients 
shows that those patients with TBI had significantly lower rates of pneumonia 
than their blunt trauma controls (Figure 2). Pneumonia rates in each cohort of 
TBI patients were reduced by approximately 20% compared to their matched 
controls. 
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Figure 2. Propensity scoring was used to match patients in the control group to the mild, 
moderate, and severe TBI group. The rate of pneumonia for each matched group was then 
calculated. Mild TBI vs. Control n=2311 in each group. Control 20.0%, Mild TBI 15.8%. 
Moderate TBI vs. Control n=694. Control 21 .3%, Moderate TBI 16.6%. Severe TBI vs Control 
n=2524. Control 20.4%, Severe TBI 15.6% *p<0.05 
Similar results were found when non-ventilated patients were matched using 
propensity scoring. There were no differences in injury severity score or 
respiratory rate, but due to the robust sample sizes, all other parameters reached 
statistical significance. Patients with mild TBI had a significantly lower incidence 
of pneumonia than controls (1.3% vs. 0.8%, TBI vs control , p <0.0001 ). 
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Moderate TBI Confers a Survival Advantage in Mice with Pneumonia 
To explore the biological mechanism by which TBI alters the susceptibility to 
pneumonia, we employed a murine model of moderate TBI with intrapulmonary 
infection with P. aeruginosa. TBI mice demonstrated a reduced mortality rate 
following the induction of post-injury pneumonia. All of the TBI mice survived the 
LD50 dose of Pseudomonas while 40% of sham animals died by 7 days (Figure 
3A). To assess whether this effect would be present with a greater infectious 
load, a second experiment was performed using 5x107 CFU P. aeruginosa 
(Figure 38). Again, mice with TBI had significantly improved survival over sham 
injury animals. Whole body plethysmography showed that TBI mice were able to 
maintain a normal tidal volume and recovered their time of inspiration faster than 
sham injury mice with pneumonia (Figure 4 ). 
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Figure 3: TBI mice are more resistant to infectious challenge than sham-injury mice. A, day 2 
sham and TBI mice received intratracheal instillation of 1 x 107 CFU of P. aeruginosa. B, day 2 
sham and TBI mice received intratracheal instillation of 5x107 CFU of P. aeruginosa. Each group 
was followed for survival for 7 days. N=10 in each group.p value determined with Log Rank test 
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Figure 4: TBI mice recover respiratory parameters faster than sham injury with pneumonia. WBP 
data showing maintenance of tidal volume and recovery of time inspiration in day2 TBI mice with 
pneumonia compared to day 2 sham injury animals with pneumonia. *p<0.05 TBI pneumonia vs 
sham + pneumonia by Bonferroni post-hoc test 
Moderate TBIIncreases Pulmonary Bacterial Clearance 
As shown in Figure 5, TBI mice had significant reductions in bacterial counts in 
both BAL fluids and lung homogenates. In addition, TBI mice had significantly 
increased cell recruitment to the lungs 4 hours after the induction of pneumonia 
(Figure 6A). Differential counts of representative cytospins prepared from the 
BAL fluid showed significant increases in both neutrophils and macrophages 
(Figure 68). Interestingly, the increased cell recruitment was not associated with 
elevated local or systemic pro-inflammatory cytokine and chemokine production. 
In fact, TBI mice had significantly lower levels of the cytokine IL-6 and the 
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chemokines MIP-2 and KC in both BAL fluids and plasma 4 hours after infection 
(Figure 7). This differs from burn and blunt trauma models which are 
accompanied by increased pro-inflammatory cytokines with increased 
macrophages and neutrophils after bacterial pneumonia. 
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Figure 5: Traumatic brain injury mice have improved bacterial clearance after IT P. aeruginosa 
challenge. Bacterial counts recovered from bronchoalveolar lavage and whole-lung homogenates 
from day 2 sham injured and TBI mice 4 hours after intratracheal administration of 1 x107 CFU of 
P. aeruginosa. *p<0.05 
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Figure 6: TBI mice recruit more cells to the alveoli compared to sham injury mice 4 hours after IT 
administration of P. aeruginosa. Day 2 sham-injured and TBI mice received IT inoculation of 
1 x 1 0 7 CFU of P. aeruginosa and bronchoalveolar lavage was performed 4 hours later. 
Bronchoalveolar cell counts measured by Beckman-Coulter particle counter and differential count 
from representative cytospins. *p<0.05 
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Figure 7: Traumatic brain injury mice produce lower levels of proinflammatory cytokines and 
chemokines in the lung and plasma in response to P. aeruginosa pneumonia. Bronchoalveolar 
lavage and plasma levels of proinflammatory cytokines from day 2 sham-injured and TBI mice 4 
hours after i.t. administration of 1 x1 07 CFU of P. aeruginosa as measured by ELISA. N=1 0 in 
each group. *p<0.05 
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Discussion 
To the best of our knowledge , the current study is the first to use propensity 
score matching to directly evaluate the risk of developing post-injury pneumonia 
in TBI patients. Using the NTDB, these results are powered by a large 
population of trauma patients from multiple institutions. Furthermore, our study is 
unique in that we evaluated mild traumatic brain injury patients as well as severe 
TBI. Previous studies have shown high rates of pneumonia, as high as 60%, in 
populations with brain injury (14, 42, 51 , 125, 132, 149). However, these studies 
focus only on severe TBI patients who require prolonged courses of mechanical 
ventilation. Our study reveals the contrary, showing significantly reduced rates of 
pneumonia in all groups of brain-injured patients when matched to non-brain-
injured blunt trauma patients. 
In our study, patients were comparatively matched to appropriate injury severity, 
length of hospital stay, age, race, vital signs, and days ventilated . Many studies 
compare a subset of severe TBI patients to non-trauma patients or the general 
population of trauma patients (23, 117). This limits the validity of these studies 
due to the differences in mechanism of injury, severity of injury, and time 
mechanically ventilated . The groups in our study focused only on trauma 
patients with or without head injury induced by a blunt mechanism. Blunt trauma 
was chosen because it is the most common mechanism of TBI. This mechanism 
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of trauma is known to cause a robust inflammatory response and changes in 
immune response (103, 107, 121, 126). 
The use of a national database has inherent limitations, including the inability to 
capture all desired data points and control for all possible patient variables. One 
such variable is the unknown history of tracheostomy, which has been shown to 
reduce the risk of subsequent ventilator-associated pneumonia if performed early 
in the hospital course (4, 17, 49, 68). Another limitation is the number of 
institutions involved in data input into the NTDB. This results in a robust sample 
population, however the inconsistency in data entry and limited definitions for 
certain entries can result in inaccuracies. Further, pneumonia is not a clearly 
defined diagnosis but is coded as a complication, therefore the criteria to 
establish and record the diagnosis of pneumonia may vary from one institution to 
another, using definitions by radiographic, BAL, or clinical score findings. 
However, this dataset is strengthened by its robust numbers and the use of 
propensity scoring to appropriately match patient populations. 
Since our clinical results are contrary to current dogma, we examined an animal 
model of head injury with subsequent pneumonia to determine the causes of 
reduced risk of pneumonia. To date, there have not been any comprehensive 
studies of bacterial pneumonia after TBI in animal models. Our studies 
demonstrate an increased resistance to P. aeruginosa pneumonia following 
traumatic brain injury. We attribute this enhanced resistance to increased 
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neutrophil recruitment to the airways resulting in faster bacterial clearance that 
allowed better respiratory function and improved survival. The neutrophil 
responses against bacteria in the lungs largely determine the outcome of 
infection, and insufficient neutrophil recruitment can lead to an inability to clear 
the infection (27, 28). Similar studies performed after burn and blunt trauma 
showed enhanced resistance to bacterial infection after injury due to increased 
neutrophil recruitment and bacterial clearance but are accompanied by significant 
increases in pro-inflammatory cytokines due to increased toll-like receptor 
signaling in macrophages and neutrophils (60, 84 ). Interestingly, there was a 
significant decrease in pro-inflammatory cytokine production during the early 
phase in our model. Because our model has increased neutrophil recruitment 
and reduced pro-inflammatory response, the observed resistance to infection is 
likely due to a different mechanism specific to TBI. Much of the basic science 
literature on immune function after TBI demonstrates serious immune depression 
(21, 40). These studies, however, focus mainly on the adaptive immune system. 
A proposed mechanism of the observed immune depression was catecholamine 
and glucocorticoid stimulated release of IL-1 0 from circulating monocytes 
inducing an anti-inflammatory state in peripheral immune cells (138) . Although 
we did not detect any increase in IL-10 levels in the plasma or airways, it is 
possible that this brain injury model is not severe enough to produce this level of 
immune suppression. 
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Pulmonary inflammation after TBI has been described in both the clinical and 
basic science literature as neurogenic pulmonary edema (NPE) (1 0, 36, 76). 
Multiple mechanisms have been implicated in the pathophysiology of post-TBI 
NPE including catecholamine storm , hydrostatic pressure increases, leukotriene 
84, and substance P (65, 108, 124 ). Further investigation into the mechanism of 
the increased neutrophil recruitment will take into account these possible 
contributing factors. 
Increased vagus nerve signaling after TBI has been shown to initiate a systemic 
anti-inflammatory response (71, 73). While our study demonstrates improved 
neutrophil recruitment and bacterial killing, the vagal anti-inflammatory pathway 
could account for the decreased levels of pro-inflammatory cytokines despite the 
presence of more inflammatory cells in the lung. The afferent and efferent 
pathways of the vagus nerve reduce the inflammatory process in stroke and 
brain injury models (73, 7 4 ). Efferent stimulation of the vagus nerve results in a 
drastic anti-inflammatory process (16, 134 ). This could serve to moderate the 
immune response resulting in less collateral damage in the lung parenchyma and 
improved survival. 
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Chapter 4: Substance Pis Responsible for Increased Neutrophil 
Recruitment in Response to Bacterial Pneumonia Following Traumatic 
Brain Injury 
Introduction 
The immune system can be "primed" by injury to respond to subsequent insults 
in an exaggerated or more effective manner. Priming has been demonstrated in 
a variety of animal models of traumatic injury with subsequent "second-hit" 
infectious or inflammatory challenges (120). Priming classically results in 
increased recruitment of activated neutrophils and inflammatory cytokine 
production in response to the second-hit (104). Toll-like receptor 4 (TLR4), an 
important sensor of bacterial lipopolysaccharide (LPS), is upregulated on 
macrophages after injury and has been shown to mediate much of the priming 
response in burn and contusion injury models (60, 84, 91 ). TLR4 upregulation 
results in more receptors being activated by LPS and thus increased activation of 
NF-kB signaling downstream. This increases macrophage proinflammatory 
cytokine production and subsequent neutrophil activation in response to lower 
levels of LPS than would be required to elicit the same response in an unprimed 
animal (91 ). 
Another important priming mediator is the neuropeptide substance P. Released 
by sensory neurons in response to injury or noxious stimuli , substance P binds 
the neurokinin-1 receptor (NK-1 R) on vascular endothelium, macrophages, 
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neutrophils, and mast cells (98). NK-1 R activation causes vasodilation, increased 
vascular permeability and adhesion molecule expression, and increased 
responsiveness to chemokine signaling (92, 106, 129). Importantly, substance P 
release alone does not induce an inflammatory reaction but requires another 
inflammatory input like bacterial products or tissue damage to activate cell 
recruitment and increase vascular permeability (20). Substance P priming is 
mediated through multiple signaling mechanisms but the best characterized 
involve potentiating of chemokine receptor signals. In one arm, NK-1 R activation 
increases NF-kB mediated expression of CXC chemokine receptors on the 
surfaces of neutrophils and increases inflammatory cytokine production in 
macrophages (106, 129). In an NF-kB-independent mechanism, substance P 
acts through the NK-1 R to enhance intracellular calcium release in response to 
chemokine binding in neutrophils (32, 1 06). Interestingly, this pathway does not 
change neutrophil activity or recruitment in the absence of chemokine stimuli 
which may explain the necessity for a second inflammatory stimulus in substance 
P priming (20, 32). 
Our previous studies in a mouse model of moderate traumatic brain injury (TBI) 
and Pseudomonas aeruginosa pneumonia found brain injury had a protective 
effect characterized by increased neutrophil recruitment and bacterial clearance 
in the lung resulting in improved survival compared to sham injury animals. 
Through propensity score matching, we also found human TBI patients were less 
likely to develop pneumonia than matched non-neurological blunt trauma 
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patients. These findings were contradictory to the prior clinical and basic science 
literature that described profound immune suppression and susceptibility to 
infection following TBI (55, 86). While TBI increased neutrophil recruitment to the 
lungs, we found significantly decreased levels of pro-inflammatory cytokine 
production both in the blood and lung that differs from the increases seen in other 
injury-primed responses ( 1 04 ). This enhanced recruitment with decreased 
cytokine production may stem from the multiple neuroimmune pathways 
activated by TBI that may result in priming through a mechanism distinct from 
other injuries. In this study we characterize the priming effect of TBI on the 
immune response to bacterial pneumonia and identify substance P signaling 
through NK-1 R as the mechanism of increased neutrophil recruitment and 
bacterial killing observed in TBI mice with pneumonia. 
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Methods 
TBI and Pneumonia Models 
As previously described in Chapter 3. 
Lung sampling and Wet/Dry ratio 
BAL and histology samples were obtained and analyzed as described in chapter 
2 with the addition of wet/dry weight ratio. The right lower lung from day 2 TBI or 
sham injury animals 4 hours was collected and weighed (wet weight). After 24 
hours of drying in an incubator at 65'C, the weight was determined again (dry 
weight) and the wet/dry weight ratio was calculated. 
Blood collection 
Blood was collected by facial vein bleed for differential count and cytokine 
analysis as described in chapter 2 from day 2 TBI or sham injury mice 4, 24, 48, 
and 96 hours after bacterial challenge with 1 x 10 7 CFU of P. aeruginosa. Arterial 
oxygen saturation was determined as described in chapter 2. 
Ex-vivo stimulation of alveolar macrophages 
48 hours after TBI or sham injury, mice were sacrificed and alveolar 
macrophages were collected by bronchoalveolar lavage. Cells were counted by 
Coulter Counter and macrophages were isolated by culturing 250,000 alveolar 
cells for 90 min in a 24-well culture plate. Cell cultures were washed 3 times with 
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sterile PBS to remove non-adherent cells. Isolated, adherent macrophages were 
then stimulated in RPM I 1640 media supplemented 10 % fetal calf serum for 18 
hours with media alone, LPS at 10 ng/ml or 100 ng/ml, or live Pseudomonas 
aeruginosa at a ratio 1:100 cells/bacteria. Supernatants were collected and 
stored at -80 C for future cytokine analysis. 
KC chemokine recruitment and CXCR2 analysis 
48 hours after TBI or sham injury, mice received 500 ng of purified KC 
chemokine (Peprotech) or normal saline by intratracheal administration. 4 hours 
later they were sacrificed and cells were collected by BAL for differential count 
and cytospin preparation as previously described in chapter 2. 
CXCR2 was measured in blood neutrophils collected by cardiac puncture from 
day 2 TBI and sham injury mice. CXCR2 levels were measured using Per-CP 
labeled anti-CXCR2 antibodies in GR1 + CD11 b+ cells and expressed as 
geometric mean of fluorescence intensity. 
Neurokinin-1 Receptor antagonist/agonist protocol 
Mice were treated with intraperitoneal injections of 25 mg/kg of the NK-1 R 
antagonist CJ-12,255 (Pfizer) or 1 mg/kg of the NK-1 R agonist GR73632 (Tocris 
Biosciences) in normal saline every 12 hours with the first dose administered 1 
hour prior to TBI or sham injury and the last dose one hour prior to IT 
administration of 5x107 or 1 x107 CFU of P. aeruginosa 48 hours after injury (29, 
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69, 114, 115). Mice receiving 5x107 CFUs were followed one week for survival 
and those receiving 1 x1 07 CFU were sacrificed one hour later for BAL collection 
of cells and bacteria as previously described in chapter 3. 
Statistical Analysis 
Column analysis was performed using two-tailed T-tests. Serial measures were 
analyzed using 2-way AN OVA with Bonferroni post- hoc test to determine 
significance between groups. 
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Results 
Hematological analysis 
Our prior studies found TBI resulted in improved neutrophil recruitment to the 
lung compared to sham injury animals at 4 hours after intratracheal 
administration of Pseudomonas aeruginosa. To determine whether this was due 
to more rapid mobilization of white blood cells into the circulation we performed 
blood count and cytokine analysis on facial vein blood samples obtained 4, 12, 
24, 48, and 96 hours after bacterial challenge from day 2 TBI or sham injury 
animals (Figure 1 ). We found a significant increase in white blood cells 48 hours 
after infection in TBI mice composed primarily of neutrophils. However, at 4 
hours after infection TBI and sham injury animals had similar white blood cell 
counts and differential counts. TBI mice also had markedly lower plasma levels 
of IL-6 and MIP-2 up to 24 hours after infection compared to sham injury animals. 
This indicated that the increase in neutrophils recruited to the lung at 4 hours in 
TBI mice with pneumonia was not the result of more neutrophils in the circulation 
but more efficient recruitment out of the circulation to the site of infection without 
increased pro-inflammatory cytokine production systemically. 
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Figure 1 : TBI mice have more circulating neutrophils 48 hours after bacterial challenge but not at 
4 hours. Hemavet counts of blood neutrophils, lymphocytes, and total white blood cells in facial 
vein blood samples from day 2 TBI and sham injury mice 4, 24, 48, and 96 hours after IT 
administration of 1 x 107 CFU of P. aeruginosa. *p<0.05 TBI vs sham by Bonferroni post-hoc test. 
Lung Injury 
Neutrophil recruitment is critical to the clearance of bacterial infection in the lungs 
but, as they accumulate in the pulmonary vasculature, they can also cause 
significant tissue damage that can progress to acute lung injury characterized by 
protein-rich edema fluid in the alveoli, atelectasis, and compromised gas 
exchange (38, 52, 82). As TBI increases the number of neutrophils recruited to 
the lung in response to bacterial pneumonia, there was the potential for 
increased damage to the lung tissue. We therefore analyzed similar parameters 
to those in chapter 2 to analyze the effect of TBI on the development of lung 
71 
injury in bacterial pneumonia. We collected arterial blood, lungs, and BAL fluid 
from day 2 TBI and sham injury mice 4 hours after IT administration of 1 x107 
CFU of P. aeruginosa to detect the presence of protein-rich edema fluid, gross 
tissue damage, atelectasis, and impaired gas exchange. Histological sections of 
lungs from the TBI mice with pneumonia demonstrated significantly less 
atelectasis, alveolar infiltration and consolidation, and tissue disruption compared 
to those from sham injury animals with pneumonia (Figure 2A). Gas exchange 
was not significantly different as shown by arterial oxygen saturation from ABG 
(Figure 28). BAL fluid from both groups showed similar protein content indicating 
that despite the presence of more neutrophils in the airways of TBI mice with 
pneumonia, there was not an increase in the protein-rich exudate that usually 
accompanies neutrophil accumulation in the lungs (Figure 2C). However, wet/dry 
weight ratios of lung tissue from TBI mice with pneumonia were significantly 
increased compared to sham injury animals with pneumonia indicating an 
increase in total lung water reflecting increased vascular permeability (Figure 
20). This indicates fluid collection in the interstitium but not the airspaces in TBI 
mice with pneumonia (83). As gas exchange and protein content of the BAL fluid 
were unchanged between groups, TBI mice have reduced lung damage by 
histology but no difference in lung injury. 
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Figure 2: TBI results in decreased lung damage and increased vascular permeability from 
bacterial pneumonia. Representative H&E stained sections of day 2 sham injury (A) and TBI (B) 
mouse lungs 4 hours after IT administration of 1 x1 07 CFU of P. aeruginosa. (C) Arterial oxygen 
saturations, (D) Total BAL protein content, and (E) WetJDry lung weight ratios for TBI and sham 
injury mice 4 hours after IT administration of 1 x 107 CFU of P. aeruginosa. *p<0.05 
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Ex-Vivo LPS and Bacterial Stimulation of Alveolar Macrophages 
To determine whether alveolar macrophages are primed by TBI to respond to 
subsequent bacterial pneumonia we collected alveolar cells from day 2 TBI and 
sham injury animals by BAL. We isolated macrophages by adhering them to 
tissue culture plates and stimulated them in culture media with different 
concentrations of purified LPS or live bacteria for 18 hours and measured the 
concentration of IL-6, MIP-2, KC, and TN F-a in the media supernatant. We found 
no significant differences in the levels of these cytokines and chemokines 
produced in response to LPS (Figure 3) or bacterial stimulus (Figure 4 ). As our 
prior in-vivo studies had found TBI mice produced lower levels of inflammatory 
cytokines in response to bacteria in the lung, these ex-vivo stimulation studies 
suggest an interaction in the lung microenvironment is responsible for decreased 
cytokine production by alveolar macrophages in TBI mice. Once removed from 
the lung, cytokine production in response to bacterial stimulus is no longer 
inhibited in alveolar macrophages from TBI mice. 
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Figure 3: Traumatic brain injury does not affect the response to LPS in alveolar macrophages. 
Levels of IL-6, TNF-a, MIP-2, and KC in culture supernatants of alveolar macrophages isolated 
from day 2 TBI or sham injury mice stimulated for 18 hours with media alone, 10 ng/ml, or 
100ng/ml of LPS. 
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Figure 4: TBI does not affect cytokine production by alveolar macrophages stimulated ex-vivo 
with live bacteria. Levels of IL-6, TNF-a , MIP-2, and KC in culture supernatants of alveolar 
macrophages isolated from day 2 TBI or sham injury mice stimulated for 18 hours with live P. 
aeruginosa. 
KC Chemokine Recruitment 
CXC chemokines are the predominant mediators of neutrophil chemotaxis. Our 
previous work found TBI mice were able to recruit more neutrophils to the lung in 
response to bacterial pneumonia despite lower levels of the CXC chemokines KC 
and MIP-2. This suggested TBI could have a sensitizing effect on neutrophil 
responsiveness to chemokine stimulus. To test this hypothesis we administered 
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purified KC chemokine or normal saline directly into the airways of day 2 TBI or 
sham injury mice. These mice were sacrificed four hours later at the peak of 
neutrophil recruitment and alveolar cells were collected by BAL for total and 
differential cell counts (Figure 5). In response to IT administration of KC, TBI 
mice recruited significantly higher numbers of cells to the airways composed 
primarily of neutrophils. This indicated that TBI results in increased neutrophil 
sensitivity to KC. 
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Figure 5: TBI increases KG-mediated neutrophil recruitment to the lung. Representative cytospins 
of BAL fluid from day 2 sham injury (A) or TBI mice (B) 4 hours after IT administration of purified 
KC. C) BAL cell counts from day 2 TBI and sham injury animals 4 hours after IT administration of 
normal saline or purified KC chemokine. *p<0.05 
To determine whether this enhanced responsiveness was due to increased 
expression of the receptor for KC, CXCR2, we analyzed blood neutrophils from 
day 2 TBI and sham injury mice by flow cytometry. As shown in Figure 6, there 
was no significant difference in CXCR2 between TBI and sham injury animals 
indicating enhanced signaling without receptor upregulation. 
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Figure 6: TBI does not increase neutrophil surface expression of CXCR2. Flow cytometry gating 
(A) and quantification (B) of CXCR2 expression on blood neutrophils from day 2 TBI or sham 
injury animals. 
NK-1 R Antagonist Treatment 
To investigate the role of substance P signaling through the neurokinin-1 
receptor in the observed improvement in survival, increased neutrophil 
recruitment, and bacterial clearance in TBI mice with pneumonia we treated mice 
with the NK-1 R antagonist CJ-12,255 or vehicle for 48 hours beginning one hour 
prior to TBI or sham injury with the final dose one hour prior to IT administration 
of 5x 107 (for survival Figure 7) or 1 x 107 CFU (neutrophil recruitment and 
bacterial clearance Figure 8) of P. aeruginosa. CJ-12,255 treatment abolished 
the survival advantage in TBI mice with pneumonia and reduced neutrophil 
recruitment and bacterial clearance to levels similar to drug and vehicle treated 
sham injury animals. 
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Figure 7: NK-1 R blockade abolishes the protective effect of TBI against bacterial pneumonia 
challenge. Day 2 sham and TBI mice treated with either vehicle or neurokinin-1 receptor 
antagonist CJ-12255 (Pfizer) were followed for survival after intratracheal administration of 5x107 
CFU of P. aeruginosa. P-value between TBI and TBI +CJ-12,255 treated mice. N=10 in each 
group. P value determined with Log Rank test. 
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Figure 8: NK-1 R blockade decreases bacterial clearance and neutrophil recruitment in TBI mice 
but not sham mice. Cell counts and CFUs in BAL fluid from vehicle or CJ-12,255 treated day 2 
sham and TBI mice 4 hours after intratracheal instillation of 1 x 107 CFU of P. aeruginosa. N=1 0 in 
each group *p<0.05 
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NK-1 R Agonist Treatment 
To further confirm the effect of NK-1 R signaling on neutrophil recruitment and 
bacterial clearance we treated sham injury animals with the NK-1 R agonist 
GR73632 following the same dosing schedule as the antagonist treatment group 
to mimic the sustained release of substance P following TBI (36, 76). NK-1 R 
agonism increased neutrophil recruitment and bacterial killing to the levels 
observed in TBI mice with pneumonia (Figure 9). This did not result in lower 
levels of MIP-2 or KC in the BAL fluid at 4 hours after pneumonia indicating NK-
1 R stimulation is not responsible for the observed decreases in chemokine 
production seen in TBI mice with pneumonia (Figure 1 0). Taken together, these 
results indicate a pivotal role for substance P signaling through NK-1 R in the 
enhanced pulmonary immune response to bacterial pneumonia following TBI. 
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Figure 9: NK-1 R stimulation increases neutrophil recruitment to the lung and bacterial killing in 
sham injury animals. A.) Cell counts and B.) CFUs in BAL fluid from day 2 sham injury mice, day 
2 TBI mice, and GR73632-treated day 2 sham mice 4 hours after intratracheal instillation of 
1 x107CFU of P. aeruginosa. 
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Figure 10: NK-1 R agonism does not affect chemokine production in the lung in sham injury 
animals with pneumonia. MIP-2 and KC in BAL fluid from day 2 sham injury mice, day 2 TBI 
mice, and GR73632-treated day 2 sham mice 4 hours after intratracheal instillation of 1 x1 07 CFU 
of P. aeruginosa. 
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Discussion 
The basic science and clinical literature surrounding TBI and immune function 
has long held that TBI causes profound immune suppression resulting in 
increased susceptibility to infection and higher rates of pneumonia in TBI patients 
compared to non-neurotrauma patients (55, 86, 140). In chapter 3 we showed in 
both human patients and an animal model of moderate TBI and bacterial 
pneumonia that prior TBI exerts a protective effect reducing the susceptibility to 
infection when compared to non-neurotrauma patients and sham injury animals 
respectively. In this study we investigated the mechanism behind the observed 
improvement in survival over sham injury animals following bacterial challenge in 
our animal model of moderate TBI and bacterial pneumonia. We found that 
substance P signaling through NK-1 R plays a critical role in TBI-induced 
neutrophil priming that leads to increased recruitment to the lung and bacterial 
killing. 
In models of non-neurological injury, a priming effect has been demonstrated that 
results in a more robust immune response to a second insult like bacterial 
infection (7, 84, 104). A common pattern is observed in these studies after injury 
consisting of increased circulating neutrophils , increased pro-inflammatory 
cytokine production by primed macrophages, and improved bacterial killing 
capacity (60, 84 ). In our model of moderate TBI followed by bacterial pneumonia 
while we did observe increased neutrophil recruitment, and increased bacterial 
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killing in TBI mice with pneumonia, we found a significant decrease in 
inflammatory cytokine production compared to sham injury mice with pneumonia. 
Through ex-vivo alveolar macrophage stimulation studies we found that 
macrophages isolated from TBI mice are only suppressed in cytokine production 
within the lung microenvironment. Outside of the lung, they respond to bacterial 
or TLR4 stimulation to the same level as those from sham injury animals. A 
possible explanation for this finding could be acetylcholine stimulation from TBI-
induced increases in vagal tone (73). Acetylcholine suppresses cytokine 
production by alveolar macrophages through the a? nicotinic receptor that 
mediates an inhibitory effect on NF-KB through c-fos activation (105, 134). As it 
is rapidly degraded, continuous stimulation with acetylcholine is required to 
sustain this effect (119). By removing the macrophages from the lung, and thus 
cholinergic stimulation, we may have relieved this inhibition allowing a return to 
cytokine production at similar levels to cells from sham injury animals. 
In this study we showed that this resulted in less lung tissue injury despite the 
presence of more neutrophils in the lung. In acute lung injury, a build-up of 
neutrophils in the pulmonary vasculature has been shown to result in premature 
neutrophil degranulation and markedly increased lung injury with progression into 
acute respiratory distress (1, 82). In our study we found increased pulmonary 
vascular permeability in our TBI mice with pneumonia over sham animals that 
may allow for more efficient egress of neutrophils from the vasculature into the 
airspaces that may prevent premature degranulation in the vasculature and result 
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in less tissue damage. Substance P release in the lungs has been demonstrated 
after TBI in association with the development of neurogenic pulmonary edema 
(36, 76, 77). Its release is triggered by increased efferent vagal signaling 
following TBI that cross-activates afferent sensory terminals to release substance 
P (77). Substance P is a potent vasodilator that may also explain the increased 
vascular permeability seen in our TBI mice with pneumonia. 
Through administration of purified KC chemokine directly into the airways of day 
2 TBI and sham injury mice we demonstrated that TBI increases neutrophil 
responsiveness to chemokine signals in a mechanism independent of increased 
CXCR2 expression. As NK-1 R blockade abolished the increase in neutrophil 
recruitment in response to pneumonia observed in TBI mice and NK-1 R 
stimulation recapitulated the increase in sham injury mice, substance P release 
following TBI is most likely responsible for this effect. NK-1 R stimulation has 
been shown to increase sensitivity to chemokine signals in two distinct ways. The 
first is increasing CXCR2 expression on neutrophils through NF-KB activation 
(129). We found no difference in CXCR2 expression between TBI and sham 
injury animals and, coupled with our other findings, this suggests that TBI has an 
inhibitory effect on NF-KB, likely through simultaneous vagal cholinergic 
stimulation, that may also account for the observed decreases in inflammatory 
cytokine production (72, 73). Substance P signaling can also increase neutrophil 
sensitivity to chemokine stimulation through its NF-KB-independent amplification 
of chemokine receptor calcium signaling (32, 54). This effect enhances sensitivity 
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to lower chemokine levels without increasing the amount of chemokine receptors 
expressed on neutrophils. 
The findings in this study identify substance P and NK-1 R as potential 
therapeutic targets to prevent or treat bacterial pneumonia. Further investigation 
of the anti-inflammatory arm of this response is necessary to elucidate the entire 
mechanism of this observed effect of TBI on the immune response to bacterial 
pneumonia. Clinical studies using agents that increase substance P levels have 
been shown to reduce the incidence of aspiration pneumonia in stroke patients 
(97). This study offers evidence that NK-1 R agonism has potential for use in 
improving treatment modalities for nosocomial pneumonias like P. aeruginosa. 
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Chapter 5: Discussion 
Traumatic brain injury is an important and complex clinical problem with 
detrimental effects beyond the nervous system (21 ). It is therefore important to 
understand the interactions between the injured brain and the peripheral organ 
systems it controls. Of particular concern in the acute management of the 
hospitalized TBI patient are the consequences of TBI on the respiratory system 
that, beyond the obvious nervous control of respiratory drive, may be 
compromised by injury from neurogenic pulmonary edema and bacterial 
pneumonia (6, 55, 148). The findings detailed in the preceding studies are 
contradictory to the current basic science and clinical literature surrounding the 
effects of traumatic brain injury on the immune system and the lungs. 
The prevailing wisdom held that, through neuroimmune interactions, TBI resulted 
in profound immune suppression that left TBI patients impaired in their defense 
against pneumonia. In a 1988 landmark study, Helling and colleagues found 50% 
of 82 head injured patients in their intensive care unit (ICU) developed at least 
one nosocomial infection during their hospitalization (55). Pneumonia 
represented 80% of these infections and the severity of head injury was 
correlated to the risk of developing pneumonia. Studies by Hsieh and Rodriguez 
found head injury to be an independent risk factor for the development of 
pneumonia in surgical ICU patients (61 , 118). Piek and colleagues expanded on 
this study to analyze records from 734 patients with an admission Glasgow coma 
88 
score :s;8 from the Nation Institute of Neurological Disorders and Stroke 
Traumatic Coma Data Bank (1 09). They found pneumonia occurred in 40.6% of 
all severe brain injury patients. Berrouane and co-workers compared 565 
patients from their ICU with and without neurotrauma and found mechanically 
ventilated TBI patients had almost double the risk of pneumonia by day 3 of their 
hospitalization compared to ventilated non-neurotrauma patients (20/1 000 
ventilator days vs 10.2/1000 ventilator days) (11 ). With so many studies 
demonstrating an increased risk of pneumonia in TBI patients, neuroimmune 
interaction was implicated in an immunosuppressive effect of TBI. 
Woiciechowsky and co-workers looked for a mechanism to explain these findings 
and used both neurosurgery patient blood samples and a rat model of TBI to 
demonstrate a catecholamine-induced release of IL-10 from monocytes following 
injury that he suggested was responsible for the observed increase in infectious 
complications (138). Kox, meanwhile, correlated EKG evidence of increased 
vagus nerve signaling to decreased inflammatory cytokine production and innate 
immune dysfunction in TBI and intracranial hemorrhage patients (73). With all of 
these studies indicating immune suppression after TBI, we expected to find an 
increase in susceptibility to bacterial pneumonia in our TBI model. Instead, we 
have demonstrated in both human patients and an animal model a protective 
effect of TBI on the development and resolution of bacterial pneumonia. Our 
findings, however, involve many of the neuroimmune interactions suggested by 
the previous literature to be immunosuppressive and injurious. Through 
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discussion of our findings in the context of the primary literature, we can integrate 
these concepts to arrive at a better understanding of TBI and the pulmonary 
immune response to infection. 
In our initial studies, we developed a mouse model of moderate TBI produced by 
impact acceleration. This was similar in severity, mechanism, and pattern of 
injury to moderate TBI seen in human patients. Our model also circumvented the 
need for skin and bone incisions found in other models of TBI. This distinction is 
important as previous studies that had demonstrated lung injury from TBI used 
models of TBI requiring skin incision and craniotomy (80, 138). These have been 
shown to induce a significant inflammatory response even without brain injury 
that could cause lung injury through the release of damage-associated molecular 
patterns (DAMPs) (22, 24, 75, 146). Our model avoids these confounding factors 
while still producing relevant brain and overlying soft tissue injury seen in frontal 
impacts in human patients and allows for study of the immune consequences of 
isolated brain injury. Our avoidance of invasive manipulation may contribute to 
the absence of lung injury we found in our mice with TBI. 
Another possible factor in the absence of lung injury in our TBI mice could be that 
our brain injury was not severe enough to cause the profound hemodynamic 
changes associated with the development of neurogenic pulmonary edema after 
TBI (47). Likely due to a catecholamine release shortly after injury, pulmonary 
vasoconstriction in NPE results in significant vascular endothelial injury that 
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serves to initiate a subsequent inflammatory response (124). We did not find 
evidence of this response in our TBI mice nor did we find elevations in IL-1 0 that 
have been shown to follow a catecholamine surge after injury (138). Through our 
later studies with NK-1 R antagonism, we suspect the neuropeptide substance P 
was released in our TBI mice and substance P release has been associated with 
the inflammation and lung injury in NPE (76, 1 08). While we did not measure 
substance P directly, the NK-1 R blockade and activation studies suggest its 
presence mediates the increased vascular permeability and neutrophil 
recruitment. However, without significant vascular endothelial injury from 
catecholamine release, the release of substance P could not induce an 
inflammatory response as it requires a second inflammatory input to recruit 
neutrophils (20). Perhaps a more severe injury would have resulted in 
catecholamine release and subsequent lung injury but we ran the risk of causing 
skull fracture and excess mortality if we increased the force of impact in our 
model. 
In chapter 3, we examined clinical data from the National Trauma Database from 
over 200,000 trauma patients and compared the rates of bacterial pneumonia 
among those with TBI and those with blunt non-neurological injuries. We found, 
as had been shown in other clinical studies, that the TBI group had a significantly 
higher incidence of pneumonia than non-neurotrauma patients (11, 55, 1 09). This 
comparison, however, ignored differences between the patient groups that may 
also have contributed to the development of pneumonia. We were comparing two 
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groups of patients as if the only variable between them were TBI or non-
neurological injury. In fact these two groups had significant difference in the 
severity of their injuries, admission vital signs, age, sex, and the amount of time 
spent in the hospital and intensive care units. Each of these variables could 
individually influence whether a patient would develop pneumonia during a 
hospitalization and could obscure the actual effect of TBI. Rodriguez showed 
significant influence of injury severity, mechanism of injury, and admission vital 
signs on the duration of hospitalization, mechanical ventilation, and most 
importantly incidence of hospital acquired pneumonia (118). We therefore 
matched our groups on the aforementioned demographic and clinical variables, 
excluding outliers until we found no significant difference between the groups in 
each category. With the confounding variables removed, we found that TBI 
patients had lower rates of pneumonia. The clinical studies by Helling, Hsieh, and 
Berrouane all used small patient groups within their respective hospitals to 
demonstrate increases in pneumonia among TBI patients (11, 55, 61 ). These 
small cohorts would not allow for the propensity score matching we performed 
and could result in biased findings. 
Of particular interest to us was matching based on injury severity score (ISS). In 
an injured patient, the severity of injury is scored in different body regions on a 
scale from 1-6 with 1 being minor injury and 6 being unsurvivable. The sum of 
the squared scores of the three most injured body regions is the ISS (90). In 
matching patients solely on the presence or absence of brain injury, other clinical 
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studies did not take into account the severity of injury as a factor that 
predisposes to the development of secondary infection (11, 55, 109). A more 
severe injury, neurological or non-neurological alike, results in longer hospital 
and ICU stays, longer periods of mechanical ventilation, and thus increased rates 
of hospital-acquired infection (41, 100, 118). Studies like those performed by 
Berrouane and Rodriguez comparing brain injury of different severity to blunt 
injury of indeterminate severity are simply not comparing similar patients (11, 
118). Even the database studies performed by Piek only organized patients by 
severity of brain injury and did not take into account the ISS of the patients (1 09). 
Without more complete characterization of the patient injury, an accurate 
representation of the risk of pneumonia is not possible. By matching patients 
using ISS in addition to demographic and vital sign data, we compared patients 
that differed only in the nature of their injury (neurological versus non-
neurological) allowing for a more accurate demonstration of the effect of TBI on 
the development of pneumonia. 
We also demonstrated a protective effect of TBI in our animal model of TBI and 
P. aeruginosa pneumonia. Our TBI mice had improved survival over sham injury 
animals following bacterial challenge in both groups. This was mediated by an 
increased neutrophil recruitment to the lungs in the acute phase (4 hours) after 
bacterial challenge that resulted in increased bacterial clearance with decreased 
lung damage in TBI mice with pneumonia. The TBI mice also produced 
significantly lower levels of pro-inflammatory cytokines in response to bacterial 
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pneumonia compared to sham injury animals with pneumonia. Decreased 
cytokine production in response to bacterial challenge after TBI has been 
suggested in the literature to be demonstrative of immune suppression. Wolach 
and Kox have demonstrated decreased production of pro-inflammatory cytokines 
by monocytes collected from peripheral blood samples of TBI patients (73, 141 ). 
Quattrochi and colleagues demonstrated in several seminal publications on T-
lymphocyte function after TBI a profound reduction in IFN-y and IL-2 production 
by lymphocytes isolated from TBI patients (111 , 112). Each of these groups 
concluded that these reductions must indicate increased susceptibility to 
infection. Our findings demonstrate that decreased cytokine production in TBI 
mice with pneumonia does not necessarily correspond to a deficit in immune 
function or increased susceptibility to infection. In our model, lower levels of 
inflammatory cytokines were associated with less lung damage and may 
represent a moderation of the inflammatory response that allows efficient 
bacterial clearance without collateral tissue damage. The observed decrease in 
inflammatory cytokine production in our study was not accompanied by an 
increase in production of the anti-inflammatory cytokine IL-1 0 as had been 
described in Woiciechowsky's studies of immune function after TBI (138, 140). 
Again, this may be due to the lesser severity of brain injury and the lack of a 
significant catecholamine release to induce the monocyte IL-1 0 production 
described in the literature (138). 
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Early neutrophil recruitment is important to the clearance of an infection and has 
been shown to improve survival in intra-abdominal sepsis (27). In the lungs, 
neutrophils are also critical to bacterial clearance but they can also cause 
significant lung injury (1, 38). Neutrophil-mediated lung injury is increased when 
neutrophils accumulate in the pulmonary vasculature before migrating into the 
airways (38). This results in early activation and degranulation that damages the 
surrounding tissues rather than the bacteria in the airways (52). In our model, we 
found that TBI mice with pneumonia had less lung damage than sham injury 
animals with pneumonia despite increased neutrophil recruitment. Our data 
suggests an increase in vascular permeability coupled with an enhanced 
responsiveness to chemokine signaling allows for more neutrophils to be 
recruited from the circulation with less accumulation in the lung vasculature. This 
prevents early degranulation and reduces tissue damage. Other studies of innate 
immune function have cited reduced neutrophil degranulation and reactive 
oxygen species release as evidence of immune suppression (141 ). Here again 
we demonstrate that this does not necessarily correspond to increased 
susceptibility to infection or an impaired immune response to bacterial infection. 
An important consideration would be whether the enhanced neutrophil 
recruitment is the result of a neutrophil or vasculature-mediated effect. Increased 
vascular permeability could result in more neutrophils gaining access to the lung 
without the need for any increased signaling or sensitivity to chemokines. 
Chemotaxis assays using neutrophils isolated from the peripheral blood of TBI or 
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sham injury mice could demonstrate differences in neutrophil migration without 
the added confounder of vasculature present in our KC instillation studies. A 
more detailed analysis of lung vascular permeability by measuring BAL albumin, 
lgM , and Evan's blue extravasation could further determine how much 
permeability is actually changed. Furthermore, depletion of neutrophils using 
anti-Ly6G antibody treatment could demonstrate whether neutrophils are critical 
to mediating the enhanced bacterial clearance at all (143). 
Substance P is a member of the tachykinins, a family of neuropeptides that are 
released in response to noxious stimuli by sensory nerve terminals (54). 
Substance P is a potent vasodilator and neutrophil chemoattractant that 
represents a mechanism for both the sensation of and response to painful or 
noxious injury. Through treatment of TBI animals with a neurokinin-1 receptor 
antagonist we found that substance P plays a critical role in the increased 
recruitment of neutrophils to the lung in response to bacterial pneumonia 
following TBI. Treated TBI mice with pneumonia died at a similar rate to sham 
injury mice with pneumonia. This decreased survival corresponded with a 
decrease in neutrophil recruitment to the lungs indicating substance P was 
responsible for the observed TBI-induced enhancement in neutrophil recruitment. 
The source of substance P in the TBI mice was likely the afferent sensory 
terminals of the vagus nerve. In a study of neurogenic pulmonary edema after 
TBI, Levasseur and colleagues found that blockade of substance P releasing 
neurons in the lung or vagotomy abolished the inflammatory arm of NPE (76). 
96 
Increased vagal efferent signaling has been demonstrated in TBI by Kox and 
colleagues and in their study they implicated as a potential cause of immune 
suppression in TBI patients as they correlated vagal activity to decreased 
cytokine production in cells of the innate immune system in TBI patients (71, 73). 
However, an important side-effect of increased efferent signaling is increased 
substance P release from the afferent limb of the vagus as was demonstrated by 
Li and colleagues using nerve stimulator electrodes to selectively stimulate 
efferent fibers of the vagus (77). The substantial substance P release they found 
in the lung linked an increase in efferent signaling to stimulation of afferent 
signaling in the vagus. 
In our initial studies of lung injury following TBI alone, substance P may have 
caused some mild vasodilation in the lungs of TBI mice but we did not detect any 
injurious effects. This is likely_due to the lack of a secondary inflammatory 
stimulus in those animals like bacteria or tissue injury (20, 32). Once we 
administered bacteria into the lungs of our TBI mice, the secondary stimulus was 
provided and substance P priming of the neutrophils and vasculature generated 
a more robust and efficient neutrophil recruitment to the lungs. Our experiments 
with IT administration of purified KC chemokine indicated that TBI mice will 
recruit more neutrophils than sham animals to the same amount of chemokine. 
With the vasculature rendered more permeable by substance P, the recruited 
neutrophils were able to cross into the airspaces and clear the bacteria there 
more efficiently and with less collateral tissue damage. In treating sham injury 
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animals with an NK-1 R agonist followed by bacterial challenge, we were able to 
reproduce the substance P priming seen in TBI mice. Agonist-treated sham injury 
animals with pneumonia demonstrated similar levels of neutrophil recruitment 
and bacterial killing to those found in TBI mice with pneumonia further proving 
substance P release is responsible for the effects of TBI on neutrophil 
recruitment in response to bacterial pneumonia. 
The findings detailed here illustrate an important divergence in the study of TBI 
and the immune system. Many studies have been geared toward limiting 
inflammation after TBI to prevent further neurological damage and improve 
functional outcome after injury (35, 36). Of particular import has been the use of 
NK-1 R antagonists to reduce cerebral edema and tissue damage following injury 
(26). These drugs are already FDA approved for use as anti-emetics and anti-
depressants and trials in TBI patients as a neuroprotective agent have been 
suggested in some studies (26, 33). While neuroprotection after TBI is an 
important area for therapeutic intervention, our findings suggest that the use of 
NK-1 R antagonists could be potentially dangerous in TBI patients. Inhibition of 
substance P signaling after TBI could remove an important element of the 
immune response to secondary infection and leave patients at risk of developing 
pneumonia or other infections (37, 85). A balance needs to be struck in 
preventing neuroinflammation but maintaining peripheral immune competence 
following TBI. 
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NK-1 R agonism already has some promising clinical applications particularly in 
pneumonia after neurological disease. Substance P has been shown to be 
critical to cough reflex and pulmonary toilet as well as the early immune response 
to bacteria in animal models of aspiration pneumonia (66, 85). Nakagawa and 
colleagues found that decreased levels of substance P in sputum samples from 
elderly patients were associated with the development of aspiration pneumonia 
(93). Arai and colleagues demonstrated that prior stroke significantly reduced 
plasma and airway levels of substance P and those patients with lower 
substance P levels were at higher risk for developing aspiration pneumonia (5). 
Nakashima and colleagues investigated the use of nicergoline, an ergotoid drug 
that has been shown to increase serum and airway levels of substance P, to 
prevent aspiration pneumonia in 60 elderly stroke patients through improved 
swallowing reflex and pulmonary toilet (94 ). This study demonstrated significant 
reduction (-30%) in aspiration pneumonia and nicergoline was found to be 
equally effective as the current regimen of angiotensin converting enzyme 
inhibitor medications used to reduce aspiration in elderly stroke patients. While 
the study cites improved swallowing and cough reflex as potential reasons for the 
decrease in pneumonia, they did not investigate any possible immune effects of 
increased substance P that could also contribute to their findings. 
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Future Work 
An important aspect of our findings that requires further investigation is the anti-
inflammatory effects of TBI on the pulmonary immune response to bacterial 
pneumonia. The observed improvement in neutrophil recruitment and bacterial 
clearance is accompanied by a moderation of the immune response manifested 
by decreased inflammatory cytokine production and decreased tissue damage. 
Treatment with the NK-1 R agonist did improve neutrophil recruitment in sham 
injury animals with pneumonia but had no effect on cytokine production. 
Substance P release has been associated with lung injury and our findings in our 
TBI model suggest a compensatory anti-inflammatory element that limits the 
injurious effects of substance P allowing for a robust but controlled response to 
bacterial pneumonia following TBI (18, 35, 98). 
A possible mechanism of the decreased cytokine production observed in our TBI 
mice with pneumonia could be cholinergic stimulation of alveolar macrophages 
and neutrophils from increased vagal parasympathetic tone following TBI (71, 
73). The vagus has been implicated as a source of immune suppression in TBI 
patients particularly of the innate immune system (71 ). Cholinergic immune 
modulation mediated through the 1 a7-acetylcholine receptor is characterized as 
decreased pro-inflammatory cytokine production (IL-6, TNF-a, chemokines) 
without a corresponding rise in IL-10 production (16, 105). This is the result of 
NF-KB inhibition through cfos activation that prevents transcription of 
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inflammatory cytokine mRNA (3, 15). Importantly, we must also consider that the 
decrease in cytokine production could be do simply to the faster clearance of 
bacteria requiring a less robust inflammatory response. Examining earlier time 
points could further identify the contributions of this possibility. 
In our model, beyond the decrease in cytokine production we also found that 
substance P signaling through NK-1 R in TBI mice was not able to increase 
neutrophil surface CXCR2 expression. This is under NF-KB control and suggests 
the presence of an inhibitory signal that does not prevent the enhanced calcium 
flux also induced by NK-1 R stimulation that occurs independent of NF-KB activity 
(3, 32, 129). We also demonstrated that the suppression of cytokine production 
in alveolar macrophages from day 2 TBI mice was not present if macrophages 
were stimulated outside of the lung. The rapid degradation of acetylcholine could 
account for this finding and supplementation of the media with acetylcholine 
would likely have resulted in suppression of cytokine production in the 
macrophages. Further investigation of the role of cholinergic signaling following 
TBI is necessary to adequately explain these observations. Our findings suggest 
investigation of combined substance P and vagal cholinergic therapy could yield 
therapeutic targets for preventing infection and improving outcomes in TBI and 
non-TBI patients alike. 
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